



Table of Contents

Policy Title	Policy Number	Last Reviewed
Adjunctive Therapies for the Healing of Dermal Wounds	299	07/01/25
Benign Skin and Subcutaneous Lesions	103	11/29/24
Cellular and/or Tissue-based Products (CTP)	227	10/11/24
Laser Therapy for Hypertrophic Scars	231	10/08/24
Pulsed Dye Laser Treatment for Dermatological Conditions	168	10/03/24
Monochromatic Phototherapy (Anodyne Therapy)	151	10/29/24
Photodynamic Therapy for Actinic Keratoses	311	02/06/25
Phototherapies for the Treatment of Skin Conditions	351	11/29/24
Radiation Therapy for Basal and Squamous Cell Carcinoma	661	08/12/24



MEDICAL POLICY

ADJUNCTIVE THERAPIES FOR THE HEALING OF DERMAL WOUNDS

Policy # 299

Implementation Date: 2/15/06

Review Dates: 5/17/07, 4/24/08, 4/23/09, 5/19/11, 6/21/12, 6/20/13, 6/11/15, 6/16/16, 6/15/17, 7/20/18, 6/10/19, 6/4/20, 6/17/21, 5/9/22, 6/2/23, 6/19/24, 7/1/25

Revision Dates: 2/9/10

Disclaimer:

1. Policies are subject to change without notice.
2. Policies outline coverage determinations for Select Health Commercial, Select Health Medicare (CMS), and Select Health Community Care (Medicaid) plans. Refer to the "Policy" section for more information.

Description

Dermal wounds are a major source of morbidity/mortality and lead to considerable disability. Acute wounds can result in the lengthening of hospitalization with associated risks for iatrogenic infections and other complications. The incidence of chronic wounds alone in the United States is approximately 5–7 million per year with the annual costs for management of these wounds estimated to be greater than \$20 billion. In addition, chronic dermal wounds can lead to complications such as infections, contractures, depression, or limb amputation.

Various adjunctive therapies are available which can be used to assist in healing of acute and chronic wounds. These include electrical stimulation, high frequency pulsed magnetic stimulation, laser, heat, radiofrequency, and ultrasound therapies. These therapies are either applied to the wound area, or across the wound for a period. Each modality proposes to speed wound-healing through ill-defined effects on cell function or circulation in the area.

COMMERCIAL PLAN POLICY AND CHIP (CHILDREN'S HEALTH INSURANCE PROGRAM)

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request.

Select Health covers electrical stimulation as an adjunct to dermal wound healing as its use in wound healing has been sufficiently demonstrated in the medical literature to show improvement in health outcomes.

Select Health does NOT cover high frequency pulsed magnetic therapy (e.g., Diapulse SofPulse), radiofrequency (e.g., The Provant Wound Closure System), laser therapy, heat therapy, or noncontact normothermic wound therapy (NNWT – e.g., the Warm-Up Active Wound Therapy System). These therapies meet the plan's definition of experimental/investigational.

Select Health does NOT cover ultrasound wound therapy for the treatment of wounds. Current evidence is weak as to the effectiveness of this technology in chronic wound management.

SELECT HEALTH MEDICARE (CMS)

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the Select Health Commercial policy applies. For the most up-to-date Medicare policies and coverage,

Adjunctive Therapies for the Healing of Dermal Wounds, continued

please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp&> or [the manual website](#)

SELECT HEALTH COMMUNITY CARE (MEDICAID)

Select Health Community Care policies typically align with State of Utah Medicaid policy, including use of InterQual. There may be situations where NCD/LCD criteria or Select Health commercial policies are used. For the most up-to-date Medicaid policies and coverage, please visit their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Summary of Medical Information

Electrical stimulation: Twelve studies on the use of electrical stimulation for chronic wounds were identified. Of these, 10 were randomized controlled trials, 7 of which involved placebo or sham conditions in which wounds were treated with an inactive electrical unit or subtherapeutic levels of electrical stimulation. The studies primarily involved patients with diabetic wounds or stage II, III, IV pressure ulcers, and 2 studies involved wounds of various types.

This literature universally supports use of electrical stimulation in management of stage II, III, and IV pressure ulcers. Wood et al., for example, used a double blind, placebo-controlled trial to examine the effect of low-intensity direct current (300–600 microA) on healing of stage II and III pressure ulcers. After 8 weeks of therapy, 58% of the ulcers treated with electrical stimulation had healed compared with 3% of the placebo group ulcers, a statistically significant difference even after accounting for surface area and ulcer depth before treatment. Kloth and Feedar randomized 16 patients to electrical stimulation therapy or to sham treatment. The mean wound size decreased $45\% \pm 23\%$ per week in the treatment group compared with a mean increase of $12\% \pm 18\%$ per week for the control group. Furthermore, all ulcers that underwent electrical stimulation healed, on average, in 7.4 ± 4.2 weeks, while none of the ulcers in the control group healed during the study period.

Peters et al. reported similar success using electrical stimulation for diabetic wounds. In a randomized, double-blind, placebo-controlled pilot study, 65% of the wounds treated with high-voltage, pulse-galvanic electric stimulation healed in the 12-week follow-up, while 35% healed with the placebo treatment, though, this difference was not statistically significant. After stratifying by compliance, 71% of adherent patients in the treatment group healed compared with 39% of adherent patients in the placebo group. Similarly, Baker et al. improved wound healing in 80 patients randomized to 2 different electrical stimulation protocols, a low-intensity stimulation placebo, or a control group that underwent standard wound care. After 5–7 weeks, the patients who underwent asymmetric electrical stimulation had a mean weekly $27\% \pm 4\%$ decrease in wound size compared to a $17\% \pm 2.7\%$ mean decrease for the placebo and control groups.

Lundeberg et al., 64 patients with venous stasis ulcers were randomly assigned to electrical stimulation or a placebo and a statistically significant decrease in wound size was seen only after 12 weeks when the average ulcer area in the test group had decreased to $39\% \pm 14\%$ of initial size vs. $59\% \pm 11\%$ of initial size for the control group. After 12 weeks, there was also a statistically significant increase in the number of wounds that had healed completely: 10 (31%) in the test group vs. 4 (13%) in the control group.

Gardner et al.'s meta-analysis of 15 studies yielded an overall weekly healing rate of 22% for electrical stimulation and 9% for control therapies. The net effect of electrical stimulation was 13% per week, an increase of 144% over the control rate. Electrical stimulation was most effective on pressure ulcers (net effect = 13%).

The literature in this area suggests that electrical stimulation is a promising adjunct therapy that may improve wound healing rates and closure incidence in patients with advanced pressure ulcers, diabetic ulcers, and venous ulcers. Most of the data regarding its effectiveness come from randomized controlled trials, many of which utilized appropriate sham or placebo treatments as comparison. As with most studies in the wound care area, this literature involved primarily small patient samples (n ranged from 16 - 100). Many of these studies did not apply any inferential statistics to evaluate the reliability of their results. The greatest weakness of this literature is inconsistency in electrical stimulation protocols across studies. Protocols varied substantially in terms of the type of electrical stimulation, the frequency of treatment

Adjunctive Therapies for the Healing of Dermal Wounds, continued

sessions, and the duration of therapy. This heterogeneity severely limits any conclusions about which protocol is most effective in improving wound healing. Currently, there are not widely accepted, standard protocols for administering electrical stimulation for wound treatment.

High frequency pulsed electromagnetic stimulation: Six studies involving electromagnetic stimulation for wound healing are included here. Four of these focused on venous ulcer healing and the other 2 examined electromagnetic treatment for pressure ulcers. Five of the 6 studies were double-blind randomized placebo-controlled trials in which patients were randomly assigned to receive actual or sham electromagnetic stimulation adjunct to conventional wound care. The largest of these trials, Leran et al., reported that venous wound healing was significantly improved in the treatment group. Among treated patients, 25% experienced wound recurrence compared to 50% of the control group. Stiller et al. reported that venous ulcers with electromagnetic stimulation experienced a 47.7% decrease in wound surface area vs. a 42.3% increase for placebo. Investigators' blinded global assessment indicated that 50% of the treated ulcers healed or markedly improved vs. 0% of the placebo-treated ulcers; none of the treated ulcers worsened compared with 54% worsening in the placebo group. Salzburg examined stage II and III pressure ulcers and reported that the treated ulcers had experienced significantly greater healing and a shorter median healing time than did untreated ulcers. In contrast, Todd et al.'s study of 19 patients with venous ulcers found no difference between treated and placebo-treated wounds in terms of healing rates of the ulcer, change in the lower leg girth, pain, or infection rates.

The primary weakness of this literature is the lack of studies involving larger sample sizes. The strongest data from a few small studies suggest that high-frequency pulsed electromagnetic stimulation may improve healing rates in venous wounds, but larger randomized clinical trials are needed before definitive conclusions regarding its efficacy and safety can be made.

Radiofrequency (Provant): Only 1 study examining this treatment modality was located in this literature search. In this randomized placebo-controlled trial of 49 patients with Stage II or III pressure ulcers, wounds treated with Provant therapy experienced improved healing over wounds treated with a sham device. Specifically, at 12 weeks, 100% of stage II wounds and 50% of stage III treated with Provant had healed vs. 36% of stage II and 14% of stage III sham-treated wounds. The closure rate for Provant-treated wounds was 11.92 ± 2.0 mm²/day and 12.9 ± 4.1 for stage II and III wounds, respectively, while the healing rate for stage II and III sham-treated wounds was 6.8 ± 1.7 and 3.6 ± 2.2 , respectively.

The results of this trial suggest that Provant may promote healing for stage II and III pressure ulcers. However, more trials are needed to adequately evaluate the long-term safety and efficacy of this treatment modality for pressure ulcers and other dermal wounds.

Laser (pulsed monochromatic light) therapy: The literature included in this review includes 7 studies. These studies focused primarily on venous ulcers, though, 1 study included wounds of various etiologies and another examined pressure ulcer healing. The 5 randomized controlled trials involving sham treatment control groups universally concluded that laser therapy had no effect on wound closure or healing rates that was statistically significant. Interestingly, a meta-analysis published in 2004 concluded that laser therapy is effective in wound healing. However, this study combined animal and human studies in its analysis. While the overall effect size was highly significant, the effect size for studies involving only humans was marginal ($d = 0.54$). This analysis also combined healing for a variety of cutaneous and non-cutaneous wound types. Thus, the specific effect of laser therapy for cutaneous wounds cannot be determined from this study.

Noncontact normothermic wound therapy (Warm-Up Active Wound Therapy): Nine studies examining the use of noncontact normothermic wound therapy (NNWT) for wound healing were included in this literature review. Of these, 7 were randomized controlled trials, 1 was a prospective cohort study, and 1 examined the cost-effectiveness of NNWT relative to standard wound care. All of the studies involved homogenous samples of chronic wound patients and examined NNWT in stage III-IV pressure ulcers, venous leg ulcers, and diabetic foot ulcers. For all the studies, the primary outcome was wound closure rate with proportion healed as an additional primary outcome in four studies. One study measured time to healing as the primary outcome.

The published literature suggests that NNWT may accelerate wound closure over standard treatments in patients with stage III or IV pressure ulcers. For example, Kloth et al. reported that the wound healing rate in pressure ulcer patients was significantly greater in those receiving NNWT (0.52 cm²/week) than for the control group (0.23 cm²/week) after 8 weeks of therapy. The incidence of closure among wounds that

Adjunctive Therapies for the Healing of Dermal Wounds, continued

completed the entire 12-week protocol was 79% (11 of 14) in NNWT patients and 50% in controls, though, this difference was statistically nonsignificant. Whitney et al. reported a significantly faster closure rate and Thomas et al. reported a higher proportion of healing in pressure ulcer patients treated with NNWT over standard wound care. Similar therapeutic results have been observed in patients with diabetic foot ulcers: NNWT can improve healing rates and the incidence of complete healing over standard wound therapy. Two studies examined NNWT in treatment for venous wounds. Robinson and Santilli's report of patients with venous wounds described greater decreases in wound size in NNWT patients over those treated with standard therapy, although the pre-study wound size was significantly higher in the treatment group ($64.4 \pm 23 \text{ cm}^2$ vs. $29.4 \pm 14 \text{ cm}^2$). Another prospective cohort study of 17 patients reported improved wound healing after 2 weeks and complete wound closure in 47% of patients after 18 months.

The literature in this area suggests that NNWT is a promising therapy that may improve wound healing rates and closure incidence in patients with advanced pressure ulcers, diabetic ulcers, and venous ulcers. However, several design and statistical issues limit conclusions about the short- and long-term effectiveness of this treatment modality. All the studies in this area involved relatively small samples (n ranged from 13–41). Furthermore, few of these studies applied any inferential statistical analysis to evaluate the reliability of their results and none utilized any procedures to blind patients or study staff to the treatment conditions. Finally, none of the studies utilized sham or placebo treatments and follow-up was confined to a fairly short time frame, typically 8–12 weeks.

Therapeutic ultrasound therapy (MIST Therapy System and Quoustic Wound Therapy System [AR1000])

Six systematic reviews examining therapeutic ultrasound (TU) for a variety of indications were identified. Two Cochrane reviews examined TU for venous leg ulcers and pressure ulcers. The 2006 review, by Baba-Akbari Sari et al., identified 3 trials involving a total of 146 patients with pressure ulcers. Two compared TU to sham therapy, and the third compared ultrasound and ultraviolet light with laser and with standard treatment. None of these studies found any statistically significant difference in wound outcomes between TU and controls, leading the authors to conclude that there is no evidence of benefit or harm of ultrasound therapy in the treatment of pressure ulcers due to the small number of trials, some with methodological limitations and small numbers of participants. In 2008, Al-Kurdi reviewed 8 trials of TU for venous leg ulcers. Five trials compared ultrasound therapy with sham ultrasound; 3 trials compared ultrasound therapy with standard treatment. No trials individually found a statistically significant difference in the number of ulcers healed but some reported that TU increases the rate of change of wound size. Pooled analyses suggested that TU healed more ulcers completely, however, and confirmed that TU reduces the size of existing ulcers. The authors concluded that TU may increase healing of venous leg ulcers, but they suggested caution as their conclusions were based on the results of eight small studies of generally poor quality.

Three reviews examined TU among multiple alternatives for treating chronic wounds. A 2001 review by Cullum et al. on behalf of the UK Public Health Service examined a variety of chronic wound therapies including TU. That review identified 10 studies on TU for pressure sores and venous leg ulcers and the reviewers concluded that there is generally insufficient reliable evidence to draw conclusions about the contribution of TU in wound healing. A similar review in 2008 by Hinchcliffe et al. offered the same conclusions about TU for diabetic foot ulcers. The authors' strongly worded conclusion observed some support for using negative pressure wound therapy and surgical excision but: "... no data were found to justify the use of any other topically applied product or dressing. Further evidence to substantiate the effect of interventions designed to enhance the healing of chronic ulcers is urgently needed. Until such evidence is available from robust trials, there is limited justification for the use of more expensive treatments and dressings." A 2008 review by Reddy et al. of treatments for pressure ulcers found one randomized controlled trial for TU. Based on this single comparative trial, the authors concluded that there are limited data to support routine use of these expensive adjunctive therapies (including TU) in managing pressure ulcers.

Finally, a 2008 review by Ramundo et al. specifically examined the efficacy of MIST therapy for debridement of chronic wounds. They systematically reviewed the literature from January 1996 to February 2008 and found insufficient evidence to determine whether ultrasonic MIST therapy effectively debrides necrotic tissue in chronic wound beds.

Adjunctive Therapies for the Healing of Dermal Wounds, continued

In addition to the systematic reviews, 22 empirical studies met criteria. Most of these were small, nonrandomized case series without a comparison group. One new comparative trial was identified that was published since the systematic reviews. Dolibog et al. examined TU in 70 patients with venous leg ulcers. Patients were randomly assigned to either compression therapy with stockings or to compression with TU (5 days after surgical intervention) once daily for 6 days a week over 7 weeks. At the end of treatment, the relative change of the total surface area (60.01% vs. 60.06%), length (39.9% vs. 43.01%), width (42.76% vs. 46.22%), and volume (80.33% vs. 82.41%), did not demonstrate any difference between the treatment and control groups, respectively.

None of the systematic reviews offer strong support for TU as treatment for chronic wounds. The only positive finding in these reviews was Al Kurdi's pooled analysis that revealed a modest advantage for TU over standard therapy. Lower extremity ulcers, particularly venous ulcers, have received the bulk of the research on TU published to date. A surprising number of randomized trials have been published, most in support of TU as an adjunct to standard therapies. However, the sample sizes in these studies are too small to permit generalization of findings to larger patient populations. Though the findings are statistically significant, they are more prone to Type I errors due to these smaller sample sizes. Thus, conclusions based on these studies are limited. Overall, the literature offers modest support for TU (including MIST and Quostic) in treatment of venous ulcers of the lower extremities but there is no support in the literature for this treatment for any other indication.

Billing/Coding Information

CPT CODES

Covered: For the conditions outlined above

Electrotherapy - Electrical Stimulation for Chronic Ulcers

- 97014** Application of a modality to one or more areas; electrical stimulation (unattended)
- 97032** Application of a modality to one or more areas; electrical stimulation (manual) (one-on-one by provider) each 15 minutes.

Not covered: Experimental/Investigational/Unproven for this use

Therapeutic Ultrasound Therapy

- 97610** Low frequency, non-contact, non-thermal ultrasound, including topical application(s), when performed, wound assessment, and instruction(s) for ongoing care, per day

HCPCS CODES

Covered: For the conditions outlined above

Electrotherapy - Electrical Stimulation for Chronic Ulcers

- G0281** Electrical stimulation, (unattended), to one or more areas, for chronic Stage III and Stage IV pressure ulcers, arterial ulcers, diabetic ulcers, and venous stasis ulcers not demonstrating measurable signs of healing after 30 days of conventional care, as part of a therapy plan of care
- E0769** Electrical stimulation or electromagnetic wound treatment device, not otherwise classified

Not covered: Investigational/Experimental/Unproven for these indications

High-Frequency Pulsed Electromagnetic Stimulation

- G0329** Electromagnetic therapy, to one or more areas for chronic State III and Stage IV pressure ulcers, arterial ulcers, diabetic ulcers and venous stasis ulcers not demonstrating measurable signs of healing after 30 days of conventional care as part of a therapy plan of care.
- E0769** Electrical stimulation or electromagnetic wound treatment device, not otherwise classified
- E0761** Non-thermal pulsed high-frequency radio waves, high peak power electromagnetic energy treatment device

Adjunctive Therapies for the Healing of Dermal Wounds, continued

Laser Therapy - Low-Level Laser or Cold Laser Therapy

S8948 Application of modality (required constant provider attendance) to one or more area; low-level laser; each 15 minutes

Non-contact Normothermic Wound Therapy (NNWT)

A6000 Non-contact wound warming cover for use with the non-contact wound warming device and warming card

E0231 Non-contact wound warming device (temperature control unit, AC adaptor and power cord) for use with warming card and wound cover

E0232 Warming care for use with the non-contact wound warming device and non-contact wound warming cover

Radiofrequency - Provant Wound Closure System

E0761 Non-thermal pulsed high-frequency radio waves, high peak power electromagnetic energy treatment device

G0329 Electromagnetic therapy, to one or more areas for chronic State III and Stage IV pressure ulcers, arterial ulcers, diabetic ulcers and venous stasis ulcers not demonstrating measurable signs of healing after 30 days of conventional care as part of a therapy plan of care

Key References

1. AHRQ. Treatment of pressure ulcers, 1994.
2. Al-Kurdi D, Bell-Syer SE, Flemming K. "Therapeutic ultrasound for venous leg ulcers." *Cochrane Database Syst Rev*. 1 (2008): CD001180.
3. Alvarez OM, Rogers RS, Booker JG, Patel M. Effect of noncontact normothermic wound therapy on the healing of neuropathic (diabetic) foot ulcers: an interim analysis of 20 patients. *J Foot Ankle Surg*. 2003; 42(1):30-5.
4. Arobella Medical LLC. Qoustic Wound Therapy System for wounds, burns and hard & soft tissues. 2010. Arobella Medical. Available: <http://www.arobella.com/products/qoustic-description.htm>. Date Accessed: December 28, 2009.
5. Baba-Akbari Sari A, Flemming K, Cullum NA, Wollina U. "Therapeutic ultrasound for pressure ulcers." *Cochrane Database Syst Rev* 3 (2006): CD001275.
6. Baker LL, Chambers R, DeMuth SK, Villar F. Effects of electrical stimulation on wound healing in patients with diabetic ulcers. *Diabetes Care*. 1997; 20(3):405-12.
7. BCBS TEC Assessment. Electrical stimulation or electromagnetic therapy as adjunctive treatments for chronic skin wounds. 2005.
8. Bell AL, Cavorsi J. "Noncontact ultrasound therapy for adjunctive treatment of nonhealing wounds: retrospective analysis." *Phys Ther* 88.12 (2008): 1517-24.
9. Berlowitz D. "Pressure ulcers: Staging; epidemiology; pathogenesis; clinical manifestations." UpToDate Online <http://www.utdol.com> (2005).
10. Berlowitz D. "Prevention and treatment of pressure ulcers." UpToDate Online <http://www.utdol.com> (2005).
11. Berlowitz D. Pressure ulcers: Staging; epidemiology; pathogenesis; clinical manifestations. UpToDate Online. 2005; <http://www.utdol.com>.
12. Berlowitz D. Prevention and treatment of pressure ulcers. UpToDate Online. 2005; <http://www.utdol.com>.
13. Carley PJ, Wainapel SF. Electrotherapy for acceleration of wound healing: low intensity direct current. *Arch Phys Med Rehabil*. 1985; 66(7):443-6.
14. Celleration Inc. MIST Ultrasound Healing Therapy. Celleration. Available: http://www.celleration.com/mist_therapy_system.html. Date Accessed: December 28, 2009.
15. Cole PS, Quisberg J, Melin MM. "Adjuvant use of acoustic pressure wound therapy for treatment of chronic wounds: a retrospective analysis." *J Wound Ostomy Continence Nurs* 36.2 (2009): 171-7.
16. Comorosan S, Vasilco R, Arghiropol M, Paslaru L, Jieanu V, Stelea S. The effect of diaphase therapy on the healing of decubitus ulcer. *Rom J Physiol*. 1993; 30(1-2):41-5.
17. Cullum N, Nelson EA, Flemming K, Sheldon T. Systematic reviews of wound care management: (5) beds; (6) compression; (7) laser therapy, therapeutic ultrasound, electrotherapy and electromagnetic therapy. *Health Technol Assess*. 2001; 5(9):1-221.
18. Cytomedix. Biological therapies for tissue repair. http://www.crystalra.com/pdf/GTF_EIO_08-24-05.pdf. 2005.
19. De Araujo T, Valencia I, Federman DG, Kirsner RS. Managing the patient with venous ulcers. *Ann Intern Med*. 2003; 138(4):326-34.
20. De Araujo TS, Hexsel CL, Kirsner RS. Treatment of Venous Ulcers. *Curr Treat Options Cardiovasc Med*. 2005; 7(2):131-138.
21. Dinno MA, Dyson M, Young SR, Mortimer AJ, Hart J, Crum LA. "The significance of membrane changes in the safe and effective use of therapeutic and diagnostic ultrasound." *Phys Med Biol* 34.11 (1989): 1543-52.
22. Dolibog P, Franek A, Taradaj J, Blaszcak E, Cierpka L. "Efficiency of therapeutic ultrasound for healing venous leg ulcers in surgically-treated patients." *Wounds: A Compendium of Clinical Research & Practice* 20.12 (2008): 334-340.
23. ECRI. Noncontact normothermic wound therapy (NNWT) for chronic wound healing. 2002.
24. Ennis WJ, Foremann P, Mozen N, Massey J, Conner-Kerr T, Meneses P. "Ultrasound therapy for recalcitrant diabetic foot ulcers: results of a randomized, double-blind, controlled, multicenter study." *Ostomy Wound Manage* 51.8 (2005): 24-39.

Adjunctive Therapies for the Healing of Dermal Wounds, continued

25. Ennis WJ, Valdes W, Gainer M, Meneses P. "Evaluation of clinical effectiveness of MIST ultrasound therapy for the healing of chronic wounds." *Adv Skin Wound Care* 19.8 (2006): 437-46.
26. Eriksson SV, Lundeberg T, Malm M. "A placebo controlled trial of ultrasound therapy in chronic leg ulceration." *Scand J Rehabil Med* 23.4 (1991): 211-3.
27. Feedar JA, Kloth LC, Gentzkow GD. Chronic dermal ulcer healing enhanced with monophasic pulsed electrical stimulation. *Phys Ther.* 1991; 71(9):639-49.
28. Flemming K, Cullum N. Therapeutic ultrasound for pressure sores. *The Cochrane Database of Systematic Reviews.* 2000; (4).
29. Food and Drug Administration. 510(k) Summary AR1000 Ultrasound Wound Therapy System. January 3, 2007 2007. FDA. Available: http://www.accessdata.fda.gov/cdrh_docs/pdf6/K062544.pdf. Date Accessed: December 28, 2009.
30. Food and Drug Administration. 510(k) Summary AS1000 Arobella Medical, LLC. April 1, 2009 2009. FDA. Available: http://www.accessdata.fda.gov/cdrh_docs/pdf9/K091038.pdf. Date Accessed: December 28, 2009.
31. Food and Drug Administration. 510(k) Summary Celleration MIST Therapy System 5.1. May 17, 2005 2005. FDA. Available: http://www.accessdata.fda.gov/cdrh_docs/pdf5/K050129.pdf. Date Accessed: December 28, 2009.
32. Food and Drug Administration. 510(k) Summary Sonoca 180/185 Wound Care System. May 21, 2008 2008. FDA. Available: http://www.accessdata.fda.gov/cdrh_docs/pdf7/K072904.pdf. Date Accessed: December 28, 2009.
33. Food and Drug Administration. Guidance for Industry and FDA Staff - Class II Special Controls Guidance Document: Low Energy Ultrasound Wound Cleaner. November 7, 2005 2005. US Department of Health and Human Services. Available: <http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm071551.htm>. Date Accessed: January 4, 2010.
34. Food and Drug Administration. Medical Devices; General and Plastic Surgery Devices; Classification of the Low Energy Ultrasound Wound Cleaner. 2005. Available: <http://edocket.access.gpo.gov/2005/05-22068.htm>. Date Accessed: January 5, 2010.
35. Franek A, Polak A, Kucharzewski M. Modern application of high voltage stimulation for enhanced healing of venous crural ulceration. *Med Eng Phys.* 2000; 22(9):647-55.
36. Gardner SE, Frantz RA, Schmidt FL. Effect of electrical stimulation on chronic wound healing: a meta-analysis. *Wound Repair Regen.* 1999; 7(6):495-503.
37. Gault WR, Gatens PF, Jr. Use of low intensity direct current in management of ischemic skin ulcers. *Phys Ther.* 1976; 56(3):265-9.
38. Gehling ML, Samies JH. "The effect of noncontact, low-intensity, low-frequency therapeutic ultrasound on lower-extremity chronic wound pain: a retrospective chart review." *Ostomy Wound Manage* 53.3 (2007): 44-50.
39. Griffin JW, Tooms RE, Mendius RA, Clift JK, Vander Zwaag R, el-Zeky F. Efficacy of high voltage pulsed current for healing of pressure ulcers in patients with spinal cord injury. *Phys Ther.* 1991; 71(6):433-42; discussion 442-4.
40. Haan J, Lucich S. "A Retrospective Analysis of Acoustic Pressure Wound Therapy: Effects on the Healing Progression of Chronic Wounds." 1.1 (2009): 28-34.
41. Hayes Inc. "Electrical stimulation for treatment of chronic nonhealing dermal ulcers." (2003).
42. Hayes Inc. Noncontact Normothermic Wound Therapy for Chronic Ulcers. 2003.
43. Hayes Inc. Noncontact normothermic wound therapy for chronic ulcers. 2003.
44. Hayes Inc. Provant® Wound Closure System (Regenesis® Biomedical Inc.). 2004.
45. Hayes Inc. Pulsed high-frequency electromagnetic energy for the treatment of chronic wounds and soft tissue injuries. 2004.
46. Hayes Inc. Pulsed Monochromatic Light Therapy for Wound Healing. 2002.
47. Hinchliffe RJ, Valk GD, Apelqvist J, et al. "A systematic review of the effectiveness of interventions to enhance the healing of chronic ulcers of the foot in diabetes." *Diabetes Metab Res Rev* 24 Suppl 1 (2008): S119-44.
48. Houghton PE, Kincaid CB, Lovell M, et al. Effect of electrical stimulation on chronic leg ulcer size and appearance. *Phys Ther.* 2003; 83(1):17-28.
49. Ieran M, Zaffuto S, Bagnacani M, Annovi M, Moratti A, Cadossi R. Effect of low frequency pulsing electromagnetic fields on skin ulcers of venous origin in humans: a double-blind study. *J Orthop Res.* 1990; 8(2):276-82.
50. Karr JC. External thermoregulation of wounds associated with lower-extremity osteomyelitis. A pilot study. *J Am Podiatr Med Assoc.* 2003; 93(1):18-22.
51. Kavros SJ, Liedl DA, Boon AJ, Miller JL, Hobbs JA, Andrews KL. "Expedited wound healing with noncontact, low-frequency ultrasound therapy in chronic wounds: a retrospective analysis." *Adv Skin Wound Care* 21.9 (2008): 416-23.
52. Kavros SJ, Miller JL, Hanna SW. "Treatment of ischemic wounds with noncontact, low-frequency ultrasound: the Mayo clinic experience, 2004-2006." *Adv Skin Wound Care* 20.4 (2007): 221-6.
53. Kavros SJ, Schenck EC. "Use of noncontact low-frequency ultrasound in the treatment of chronic foot and leg ulcerations: a 51-patient analysis." *J Am Podiatr Med Assoc* 97.2 (2007): 95-101.
54. Kenkre JE, Hobbs FD, Carter YH, Holder RL, Holmes EP. A randomized controlled trial of electromagnetic therapy in the primary care management of venous leg ulceration. *Fam Pract.* 1996; 13(3):236-41.
55. Kloth LC, Berman JE, Nett M, Papanek PE, Dumit-Minkel S. A randomized controlled clinical trial to evaluate the effects of noncontact normothermic wound therapy on chronic full-thickness pressure ulcers. *Adv Skin Wound Care.* 2002; 15(6):270-6.
56. Kloth LC, Feedar JA. Acceleration of wound healing with high voltage, monophasic, pulsed current. *Phys Ther.* 1988; 68(4):503-8.
57. Kopera D, Kokol R, Berger C, Haas J. Does the use of low-level laser influence wound healing in chronic venous leg ulcers? *J Wound Care.* 2005; 14(8):391-4.
58. Lagan KM, McKenna T, Witherow A, Johns J, McDonough SM, Baxter GD. Low-intensity laser therapy/combined phototherapy in the management of chronic venous ulceration: a placebo-controlled study. *J Clin Laser Med Surg.* 2002; 20(3):109-16.
59. Lundeberg T, Malm M. Low-power HeNe laser treatment of venous leg ulcers. *Ann Plast Surg.* 1991; 27(6):537-9.
60. Lundeberg T, Nordstrom F, Brodda-Jansen G, Eriksson SV, Kjartansson J, Samuelson UE. "Pulsed ultrasound does not improve healing of venous ulcers." *Scand J Rehabil Med* 22.4 (1990): 195-7.
61. Lundeberg TC, Eriksson SV, Malm M. Electrical nerve stimulation improves healing of diabetic ulcers. *Ann Plast Surg.* 1992; 29(4):328-31.
62. Macario A, Dexter F. Is noncontact normothermic wound therapy cost effective for the treatment of stages 3 and 4 pressure ulcers? *Wounds.* 2002; 14(3):93-106.

Adjunctive Therapies for the Healing of Dermal Wounds, continued

63. Malm M, Lundeberg T. Effect of low power gallium arsenide laser on healing of venous ulcers. *Scand J Plast Reconstr Surg Hand Surg*. 1991; 25(3):249-51.
64. McCulloch D. Management of diabetic foot lesions. UpToDate Online. 2005; <http://www.uptodate.com/>.
65. McCulloch DK. "Evaluation of the diabetic foot." UpToDate Online <http://www.uptodate.com> (2005).
66. McCulloch J, Knight CA. Noncontact normothermic wound therapy and offloading in the treatment of neuropathic foot ulcers in patients with diabetes. *Ostomy Wound Manage*. 2002; 48(3):38-44.
67. Mohr P, Stegmann W, Breitbart EW. "Low-frequency ultrasound treatment of chronic venous ulcers." *Wound Repair Regen* 5.1 (1997): 18-22.
68. National Pressure Ulcer Advisory Panel. "Stages of Wounds." Ed. <http://www.ldhpmc.com/Wound%20Stages.htm>, 2003.
69. Paletta C, Massey B. Vascular ulcers. EMedicine Website. 2005; <http://www.emedicine.com/plastic/topic467.htm>.
70. Peschen M, Weichenthal M, Schopf E, Vanscheidt W. "Low-frequency ultrasound treatment of chronic venous leg ulcers in an outpatient therapy." *Acta Derm Venereol* 77.4 (1997): 311-4.
71. Peters EJ, Lavery LA, Armstrong DG, Fleischli JG. Electric stimulation as an adjunct to heal diabetic foot ulcers: a randomized clinical trial. *Arch Phys Med Rehabil*. 2001; 82(6):721-5.
72. Posten W, Wronne DA, Dover JS, Amdt KA, Silapunt S, Alam M. Low-level laser therapy for wound healing: mechanism and efficacy. *Dermatol Surg*. 2005; 31(3):334-40.
73. Ramundo J, Gray M. "Is ultrasonic mist therapy effective for debriding chronic wounds?" *J Wound Ostomy Continence Nurs* 35.6 (2008): 579-83.
74. Reddy M, Gill SS, Kalkar SR, Wu W, Anderson PJ, Rochon PA. "Treatment of pressure ulcers: a systematic review." *Jama* 300.22 (2008): 2647-62.
75. Regeneration Biomedical. <http://www.regenesisbiomedical.com/>. Date Accessed: 1/12/06. 2005.
76. Ritz MC, Gallegos R, Canham MB, Eskalai M, George FR. PROVANT Wound-Closure System accelerates closure of pressure wounds in a randomized, double-blind, placebo-controlled trial. *Ann N Y Acad Sci*. 2002; 961:356-9.
77. Robinson C, Santilli SM. Warm-Up Active Wound Therapy: a novel approach to the management of chronic venous stasis ulcers. *J Vasc Nurs*. 1998; 16(2):38-42.
78. Salzberg CA, Cooper-Vastola SA, Perez F, Viehbeck MG, Byrne DW. The effects of non-thermal pulsed electromagnetic energy on wound healing of pressure ulcers in spinal cord-injured patients: a randomized, double-blind study. *Ostomy Wound Manage*. 1995; 41(3):42-4, 46, 48 passim.
79. Samies J, Gehling M. "Acoustic pressure wound therapy for management of mixed partial- and full-thickness burns in a rural wound center." *Ostomy Wound Manage* 54.3 (2008): 56-9.
80. Samson D, Lefevre F, Aronson N. Wound-Healing Technologies: Low-Level Laser and Vacuum-Assisted Closure. Rockville, MD: Summary, Evidence Report/Technology Assessment No. 111. (Prepared by the Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center, under Contract No. 290-02-0026). AHRQ Publication No.05-E005-1. Rockville, MD: Agency for Healthcare Research and Quality, 2004.
81. Santilli SM, Valusek PA, Robinson C. Use of a noncontact radiant heat bandage for the treatment of chronic venous stasis ulcers. *Adv Wound Care*. 1999; 12(2):89-93.
82. Schindl M, Kerschhan K, Schindl A, Schon H, Heinzel H, Schindl L. Induction of complete wound healing in recalcitrant ulcers by low-intensity laser irradiation depends on ulcer cause and size. *Photodermatol Photoimmunol Photomed*. 1999; 15(1):18-21.
83. Schmuckler J. "Acoustic pressure wound therapy to facilitate granulation tissue in sacral pressure ulcers in patients with compromised mobility: a case series." *Ostomy Wound Manage* 54.8 (2008): 50-3.
84. Stiller MJ, Pak GH, Shupack JL, Thaler S, Kenny C, Jondreau L. A portable pulsed electromagnetic field (PEMF) device to enhance healing of recalcitrant venous ulcers: a double-blind, placebo-controlled clinical trial. *Br J Dermatol*. 1992; 127(2):147-54.
85. Taly AB, Sivaraman Nair KP, Murali T, John A. Efficacy of multiwavelength light therapy in the treatment of pressure ulcers in subjects with disorders of the spinal cord: A randomized double-blind controlled trial. *Arch Phys Med Rehabil*. 2004; 85(10):1657-61.
86. Tan J, Abisi S, Smith A, Bumand KG. "A painless method of ultrasonically assisted debridement of chronic leg ulcers: a pilot study." *Eur J Vasc Endovasc Surg* 33.2 (2007): 234-8.
87. Taradaj J, Franek A, Brzezinska-Wcislo L, et al. "The use of therapeutic ultrasound in venous leg ulcers: a randomized, controlled clinical trial." *Phlebology* 23.4 (2008): 178-83.
88. ter Riet G, Kessels AG, Knipschild P. "A randomized clinical trial of ultrasound in the treatment of pressure ulcers." *Phys Ther* 76.12 (1996): 1301-11.
89. Thawer H. Wound assessment and the effects of ultrasound on impaired wound healing. University of Western Ontario (Canada); 2002.
90. The Cleveland Clinic Foundation. Lower extremity ulcers. <http://www.clevelandclinic.org/health/health-info/docs/3300/3313.asp?index=11311&src=news>. 2003.
91. Thomas DR, Diebold MR, Eggemeyer LM. A controlled, randomized, comparative study of a radiant heat bandage on the healing of stage 3-4 pressure ulcers: a pilot study. *J Am Med Dir Assoc*. 2005; 6(1):46-9.
92. Thomas R. "Acoustic pressure wound therapy in the treatment of stage II pressure ulcers." *Ostomy Wound Manage* 54.11 (2008): 56-8.
93. Todd DJ, Heylings DJ, Allen GE, McMillin WP. Treatment of chronic varicose ulcers with pulsed electromagnetic fields: a controlled pilot study. *Ir Med J*. 1991; 84(2):54-5.
94. Waldrop K, Serfass A. "Clinical effectiveness of noncontact, low-frequency, nonthermal ultrasound in burn care." *Ostomy Wound Manage* 54.6 (2008): 66-9.
95. Whitney JD, Salvadalena G, Higa L, Mich M. Treatment of pressure ulcers with noncontact normothermic wound therapy: healing and warming effects. *J Wound Ostomy Continence Nurs*. 2001; 28(5):244-52.
96. Wood JM, Evans PE, 3rd, Schallreuter KU, et al. A multicenter study on the use of pulsed low-intensity direct current for healing chronic stage II and stage III decubitus ulcers. *Arch Dermatol*. 1993; 129(8):999-1009.
97. Woodruff LD, Bounkeo JM, Brannon WM, et al. The efficacy of laser therapy in wound repair: a meta-analysis of the literature. *Photomed Laser Surg*. 2004; 22(3):241-7.
98. Wound Ostomy and Continence Nurses Society. (Wound, Ostomy, and Continence Nurses Society). Guideline for management of wounds in patients with lower-extremity neuropathic disease. 2004.

Adjunctive Therapies for the Healing of Dermal Wounds, continued

99. Wound Ostomy and Continence Nurses Society. (Wound, Ostomy, and Continence Nurses Society). Guideline for management of wounds in patients with lower-extremity venous disease.

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate healthcare providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Select Health® makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. Select Health updates its Coverage Policies regularly, and reserves the right to amend these policies without notice to healthcare providers or Select Health members.

Members may contact Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Coverage Policy may call Select Health Provider Relations at (801) 442-3692.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Select Health.

"Intermountain Healthcare" and its accompanying logo, the marks of "Select Health" and its accompanying marks are protected and registered trademarks of the provider of this Service and or Intermountain Health Care, Inc., IHC Health Services, Inc., and Select Health, Inc. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association



MEDICAL POLICY

BENIGN SKIN AND SUBCUTANEOUS LESIONS

Policy # 103

Implementation Date: 7/1/98

Review Dates: 9/18/00, 11/1/01, 8/28/02, 6/25/03, 9/8/03, 10/23/03, 6/24/04, 5/17/05, 5/3/06, 5/17/07, 4/24/08, 4/23/09, 4/22/10, 9/23/11, 11/29/12, 10/24/13, 10/14/14, 10/15/15, 10/20/16, 11/27/18, 12/18/19, 12/17/20, 12/15/21, 1/13/23, 12/22/23, 11/29/24

Revision Dates: 9/8/03, 9/23/11, 2/8/17, 6/5/17

Related Medical Policies:

[#168 Laser Treatment of Congenital Hemangiomas \(Port Wine Stains\)](#)

[#231 Treatment of Keloids](#)

[#237 Cryosurgical Ablation of Plantar Fasciitis, Morton's Neuromas and other Conditions of the Feet](#)

[#424 Sclerotherapy for the Management of Lymphangiomas](#)

Disclaimer:

1. Policies are subject to change without notice.
2. Policies outline coverage determinations for Select Health Commercial, Select Health Advantage (Medicare/CMS), and Select Health Community Care (Medicaid/CHIP) plans. Refer to the "Policy" section for more information.

Description

Adult patients frequently seek removal of skin lesions that cause them to feel concern about possible skin malignancies such as malignant melanoma, atypical nevi (dysplastic nevi), squamous cell carcinoma, basal cell carcinoma, and other non-melanoma skin cancers. However, these lesions may be found to be benign, non-malignant lesions. Subsequently, after evaluation/removal non-covered treatment codes are sometimes used. This can lead to the denial of claims for services.

A lipoma is a benign fatty tumor usually composed of mature fat cells, that can involve the dermis, epidermis, and subcutaneous tissues, and is rarely found below the fascia (i.e., sub-fascial and sub-muscular). Most of these lesions are below the skin (dermis) but above the fascia.

Additionally, patients also often seek treatment for known, benign skin lesions such as 'skin tags' due to symptoms of skin irritation, pain, recurrent infections or changing character of the lesion.

COMMERCIAL PLAN POLICY AND CHIP (CHILDREN'S HEALTH INSURANCE PROGRAM)

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request.

Select Health covers the removal of lipomas, seborrheic keratoses, melanocytic nevi, acrochordons/skin tags, fibromas, and dermatofibromas in adults when found to be medically necessary based upon documentation of a functional* problem.

Some benign skin conditions present predominantly in children such as congenital hemangiomas, port wine stains, and other vascular lesions, which may only be covered under specific conditions identified in policies specific to those conditions.

Specific lesions not shown to have a covered functional* problem are denied, based on the reconstructive and cosmetic limitations present in the plan certificate of coverage.

Benign Skin and Subcutaneous Lesions, continued

*Functional impairment is defined as symptoms of such magnitude, or locations of the lesion, that it impairs an individual's ability to perform ADLs, limits mobility, or otherwise prevents normal function of a body part. Symptoms may include, but are not limited to, pain, tenderness, itch (pruritus), ulceration, bleeding, frequent irritation, active inflammation, and restriction of movement to avoid symptoms.

SELECT HEALTH MEDICARE

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the Select Health Commercial policy applies. For the most up-to-date Medicare policies and coverage, please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp&> or the manual website

SELECT HEALTH COMMUNITY CARE (MEDICAID)

Coverage is determined by the State of Utah Medicaid program; if Utah State Medicaid has no published coverage position and InterQual criteria are not available, the Select Health Commercial criteria will apply. For the most up-to-date Medicaid policies and coverage, please visit their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Summary of Medical Information

The skin is an anatomically complex organ subject to the occurrence of a wide spectrum of nevi and neoplasms that may be malignant, potentially malignant, or benign. Diagnosis and treatment of benign or potentially malignant skin lesions requires significant expertise. Although many of these skin lesions do not need treatment, some benign or potentially malignant nevi and neoplasms, cysts, or reactive lesions require medical or surgical intervention for accurate clinical and/or histological diagnosis, to rule out malignancy, to treat or prevent complications, such as infection, ulceration, bleeding, or further enlargement of the lesion, for relief of symptoms of irritation, tenderness, or pain, for avoidance or correction of disfigurement, to prevent progression to frank malignancy, or to rule out benign infiltrative or other reactive processes.

If there is a question of diagnosis or possible malignancy, one or more lesions are submitted for histological evaluation. In some cases, special stains, histochemical or immunohistochemical staining, or microbiologic techniques may be needed. Occasionally electron microscopy may give additional information.

In the case in which the patient has multiple lesions known to be benign (e.g., multiple seborrheic keratosis, multiple fibroepitheliomas, papillomas [skin tags], and others), removal or destruction without biopsy of all lesions is customary practice.

Accurate diagnosis and proper management of benign, potentially malignant, or premalignant skin lesions often require significant expertise. Physicians should be familiar with the clinical presentation of these lesions, and it is often helpful to correlate the clinical presentation (the "gross pathology") with the histological changes (the "microscopic pathology") in these lesions and disorders.

The treatment will vary depending on multiple factors, including lesion type and location and may include the medical treatments such as topical or systemic medications, intralesional injections, radiotherapy or surgical treatments such as excision, shave biopsy, shave removal, saucerization, destruction using cryotherapy, electrocautery, or chemical or laser therapy. Dermabrasion and liposuction are also methods used to treat these conditions but are generally used only for cosmetic advantage not for any improved outcome over other methods of removing the lesions. Except under unusual circumstances (e.g., large size, multiplicity of lesions, location in anatomically sensitive body areas, and prior medical or psychological condition of the patient or other unusual circumstances) management of benign, potentially malignant, or premalignant lesions is usually carried out in private physician offices or outpatient clinics. Patients with certain medical conditions such as those with cardiopulmonary problems in which close monitoring are indicated may be admitted to an ambulatory surgical center or hospital.

Benign Skin and Subcutaneous Lesions, continued

Billing/Coding Information

Covered: For the conditions outlined above

CPT CODES

11400	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), trunk, arms or legs; excised diameter 0.5 cm or less
11401	; excised diameter 0.6 to 1.0 cm
11402	; excised diameter 1.1 to 2.0 cm
11403	; excised diameter 2.1 to 3.0 cm
11404	; excised diameter 3.1 to 4.0 cm
11406	; excised diameter over 4.0 cm
11420	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), scalp, neck, hands, feet, genitalia; excised diameter 0.5 cm or less
11421	; excised diameter 0.6 to 1.0 cm
11422	; excised diameter 1.1 to 2.0 cm
11423	; excised diameter 2.1 to 3.0 cm
11424	; excised diameter 3.1 to 4.0 cm
11426	; excised diameter over 4.0 cm
11440	Excision, other benign lesion including margins, except skin tag (unless listed elsewhere), face, ears, eyelids, nose, lips, mucous membrane; excised diameter 0.5 cm or less
11441	; excised diameter 0.6 to 1.0 cm
11442	; excised diameter 1.1 to 2.0 cm
11443	; excised diameter 2.1 to 3.0 cm
11444	; excised diameter 3.1 to 4.0 cm
11446	; excised diameter over 4.0 cm
21011	Excision, tumor, soft tissue of face or scalp, subcutaneous; less than 2 cm
21012	; 2 cm or greater
21552	Excision, tumor, soft tissue of neck or anterior thorax, subcutaneous; 3 cm or greater
21555	; less than 3 cm
21930	Excision, tumor, soft tissue of back or flank, subcutaneous; less than 3 cm
21931	; 3 cm or greater
22902	Excision, tumor, soft tissue of abdominal wall, subcutaneous; less than 3 cm
22903	; 3 cm or greater
23071	Excision, tumor, soft tissue of shoulder area, subcutaneous; 3 cm or greater
23075	; less than 3 cm
24071	Excision, tumor, soft tissue of upper arm or elbow area, subcutaneous; 3 cm or greater
24075	; less than 3 cm
25071	Excision, tumor, soft tissue of forearm and/or wrist area, subcutaneous; 3 cm or greater
25075	; less than 3 cm
26111	Excision, tumor or vascular malformation, soft tissue of hand or finger, subcutaneous; 1.5 cm or greater

Benign Skin and Subcutaneous Lesions, continued

26115	; less than 1.5 cm
27043	Excision, tumor, soft tissue of pelvis and hip area, subcutaneous; 3 cm or greater
27047	; less than 3 cm
27327	Excision, tumor, soft tissue of thigh or knee area, subcutaneous; less than 3 cm
27337	; 3 cm or greater
27618	Excision, tumor, soft tissue of leg or ankle area, subcutaneous; less than 3 cm
27632	; 3 cm or greater
28039	Excision, tumor, soft tissue of foot or toe, subcutaneous; 1.5 cm or greater
28043	; less than 1.5 cm

If a lipoma is below the epidermis, dermis, and subcutaneous layers of skin (i.e., in a sub-fascial or a sub-muscular tissue) the appropriate codes are listed below:

21013	Excision, tumor, soft tissue of face and scalp, subfascial (eg, subgaleal, intramuscular); less than 2 cm
21014	; 2 cm or greater
21554	Excision, tumor, soft tissue of neck or anterior thorax, subfascial (eg, intramuscular); 5 cm or greater
21556	; less than 5 cm
21932	Excision, tumor, soft tissue of back or flank, subfascial (eg, intramuscular); less than 5 cm
21933	; 5 cm or greater
22900	Excision, tumor, soft tissue of abdominal wall, subfascial (eg, intramuscular); less than 5 cm
22901	; 5 cm or greater
23073	Excision, tumor, soft tissue of shoulder area, subfascial (eg, intramuscular); 5 cm or greater
23076	; less than 5 cm
24073	Excision, tumor, soft tissue of upper arm or elbow area, subfascial (eg, intramuscular); 5 cm or greater
24076	; less than 5 cm
26113	Excision, tumor, soft tissue, or vascular malformation, of hand or finger, subfascial (eg, intramuscular); 1.5 cm or greater
26116	; less than 1.5 cm
27045	Excision, tumor, soft tissue of pelvis and hip area, subfascial (eg, intramuscular); 5 cm or greater
27048	; less than 5 cm
27328	Excision, tumor, soft tissue of thigh or knee area, subfascial (eg, intramuscular); less than 5 cm
27339	; 5 cm or greater
27619	Excision, tumor, soft tissue of leg or ankle area, subfascial (eg, intramuscular); less than 5 cm
27634	; 5 cm or greater
28041	Excision, tumor, soft tissue of foot or toe, subfascial (eg, intramuscular); 1.5 cm or greater

Benign Skin and Subcutaneous Lesions, continued

28045 ; less than 1.5 cm

HCPCS CODES

No specific codes identified

Key References

1. American Academy of Dermatology: Referral Guidelines for approach to the treatment of non-melanocytic nevi, hematoma, neoplasms, and other potentially neoplastic lesions/95

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate healthcare providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Select Health® makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. Select Health updates its Coverage Policies regularly, and reserves the right to amend these policies without notice to healthcare providers or Select Health members.

Members may contact Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Coverage Policy may call Select Health Provider Relations at (801) 442-3692.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Select Health.

"Intermountain Healthcare" and its accompanying logo, the marks of "Select Health" and its accompanying marks are protected and registered trademarks of the provider of this Service and or Intermountain Health Care, Inc., IHC Health Services, Inc., and Select Health, Inc. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association



MEDICAL POLICY

CELLULAR AND/OR TISSUE-BASED PRODUCTS (CTP)

Policy # 227

Implementation Date: 5/1/04

Review Dates: 4/14/05, 6/22/06, 5/17/07, 4/24/08, 4/23/09, 5/19/11, 6/20/11, 6/20/13, 4/17/14, 10/20/16, 10/19/17, 10/25/18, 10/7/19, 10/14/20, 11/27/21, 9/15/22, 10/10/23, 10/11/24

Revision Dates: 2/24/05, 2/18/10, 4/21/15, 7/18/18, 12/31/19, 10/1/20, 10/14/21, 10/14/22, 4/7/23

Disclaimer:

1. Policies are subject to change without notice.
2. Policies outline coverage determinations for Select Health Commercial, Select Health Advantage (Medicare/CMS), and Select Health Community Care (Medicaid/CHIP) plans. Refer to the "Policy" section for more information.

Description

Cellular and/or tissue-based products (CTP), also referred to as synthetic skin substitutes, are tissue-engineered products using living cells, such as fibroblasts and keratinocytes, in a scaffold of natural or synthetic extracellular matrices. These matrices provide mechanical stability and a three-dimensional framework for eventual tissue infiltration and development; and can also promote wound healing by stimulating the host to produce a variety of cytokines. Scaffolds are characterized as biodegradable, natural, or synthetic. Synthetic scaffolds, such as polyglycolic acid and polylactic acid, are often manufactured on a large scale.

Tissue-engineered skin substitutes can be broadly categorized into epidermal components alone, mainly dermal components, or composite grafts (containing both epidermal and dermal components). Epidermal skin substitutes consist of grafts of cultured epidermal cells with no dermal components. These products are often characterized by prolonged culture time and handling difficulties. Dermal skin substitutes help prevent wound contraction and offer greater mechanical stability. Numerous products have been developed for various applications.

COMMERCIAL PLAN POLICY AND CHIP (CHILDREN'S HEALTH INSURANCE PROGRAM)

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request.

Select Health covers *certain* synthetic skin substitutes as the medical literature has demonstrated use of this technology to be a cost-effective alternative to standard therapies, and which have also demonstrated improvement in the health outcomes of patients.

Select Health covers the following synthetic skin substitutes:

- 1- AlloDerm
- 2- AlloSkin
- 3- Alloskin RT
- 4- Apligraf
- 5- Arthroflex
- 6- Cortiva
- 7- Cymetra
- 8- Cytal
- 9- DermACELL

Cellular and/or Tissue-based Products (CTP), continued

- 10- Dermagraft
- 11- Epifix (Non-injectable)
- 12- Epiburn
- 13- FlexHD, AllopatchHD, Matrix HD
- 14- GammaGraft
- 15- Grafix
- 16- GraftJacket
- 17- Hyalomatrix
- 18- Innovamatrix
- 19- Integra bilayer matrix wound dressing
- 20- Integra dermal regeneration template
- 21- Integra flowable wound matrix
- 22- Integra Matrix
- 23- MatriStem micromatrix
- 24- MemoDerm, DermaSpan, TranZgraft, or InteguPlyOasis burn matrix
- 25- Novafix
- 26- Oasis wound matrix
- 27- Oasis ultra tri-layer wound matrix
- 28- Phasix Mesh/Phasix ST Mesh
- 29- PriMatrix
- 30- Restrata
- 31- Talymed
- 32- TheraSkin

All other synthetic skin substitutes not mentioned above, and with no specific HCPCS code, will be considered investigational/experimental, and therefore, will not be covered.

SELECT HEALTH MEDICARE

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the Select Health Commercial policy applies. For the most up-to-date Medicare policies and coverage, please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp&> or the manual website

SELECT HEALTH COMMUNITY CARE (MEDICAID)

Coverage is determined by the State of Utah Medicaid program; if Utah State Medicaid has no published coverage position and InterQual criteria are not available, the Select Health Commercial criteria will apply. For the most up-to-date Medicaid policies and coverage, please visit their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Summary of Medical Information

This topic was thoroughly reviewed in the Hayes Report dated February 2004. This review covered a myriad of skin substitutes currently available, identifying those that have shown positive outcomes with regards to wound healing in difficult and complex patients and those with inadequate literature support to address outcomes. This study identified that some evidence from a limited number of randomized controlled trials demonstrates that Apligraf can improve the speed of healing and complete healing rate in patients with chronic venous ulcers. There is also evidence from randomized controlled trials that both

Cellular and/or Tissue-based Products (CTP), continued

Apligraf and Dermagraft can improve healing of diabetic foot ulcers that have failed standard wound care. These skin substitutes are used in conjunction with standard wound care and are not considered first-line therapy; they are used in patients who have not responded adequately to appropriate standard therapy. There is also some evidence to support the use of these and other skin substitute products in patients with other types of wounds, such as thermal burns, skin graft donor site wounds, and acute surgical wounds. However, the evidence regarding these other indications is very limited and of lesser quality, and additional randomized controlled studies will be required to establish the safety and efficacy of skin substitutes for other types of wounds and to define appropriate patient selection criteria.

An additional economic analysis by Schonfeld et al. published in 2000 indicates the cost effectiveness of the use of this technology, specifically Apligraf. This provides further support for the use of skin substitutes. This study is limited in its generalization, as only the Apligraf skin substitute was evaluated, and the comparison was made to conservative therapy rather than other skin grafting options. Nonetheless, this provides evidence to support use of these technologies.

Information derived from the Hayes February 2004 Review regarding specific synthetic skin substitute reveals the following:

AlloDerm: The safety and efficacy of AlloDerm was evaluated in two studies, including one small, randomized trial and one somewhat larger uncontrolled study. Both studies involved patients with burns; AlloDerm was used either in conjunction with a thin allograft or was used to cover the donor site. Results were positive and demonstrated that this skin substitute may speed healing and reduce scar formation in patients who require skin grafting. However, these were both small studies and do not provide definitive proof that AlloDerm is superior to conventional grafting or enough evidence to define patient selection criteria.

Apligraf: The strongest evidence regarding the efficacy of the different skin substitutes is for the use of Apligraf in the treatment of chronic venous leg ulcers. Results of three randomized trials suggest that Apligraf can significantly reduce the time to complete healing of chronic venous leg ulcers compared with standard treatment. In one study, Apligraf was significantly more effective than compression therapy for patients with large ulcers (> 1000 mm²), patients with deeper ulcers, and patients with ulcers of > 6 months' duration. However, in the same study, standard compression was as efficacious as Apligraf combined with compression therapy in a subgroup of patients with venous ulcers of < 6 months' duration, suggesting that the most benefit of Apligraf is for patients with large or deep ulcers and for patients with chronic ulcers. One author stated that Apligraf is not recommended for first-line therapy since most patients with small, noninfected ulcers of short duration would be expected to heal by compression therapy alone.

There was also relatively good, albeit limited, evidence from two randomized controlled studies that demonstrated efficacy of Apligraf in the healing of diabetic foot ulcers. Both studies found that treatment with Apligraf significantly increased the complete wound healing rate in patients with diabetic foot ulcers. Even though Apligraf has been investigated in a number of patients with acute excisional wounds, the evidence to support the routine use of Apligraf in these patients is weak. In a multicenter, uncontrolled trial of patients with acute excisional wounds that would otherwise require grafting or healing by secondary intention (n=110), Apligraf was well-tolerated, and showed no signs of clinical rejection, and performed as well as or better than autografts in approximately 50% of patients.

However, these findings were based on subjective impressions, with no analysis of the reliability of the responses. In a pair comparison, randomized controlled trial (n=20) comparing the efficacy of Apligraf for healing acute, partial-thickness donor site wounds with that of autografts and polyurethane film occlusive dressings, the time to complete healing, pain relief, and cosmetic outcomes were similar for sites treated with Apligraf and autograft, whereas polyurethane film resulted in a longer time to healing and a poorer cosmetic outcome. However, due to the preliminary nature and the small size of this study, the relevance of the results to other patient populations cannot be readily determined. Additional data from well-designed trials are needed before definitive conclusions can be reached. In one study of patients with acute excisional wounds, the clinical persistence of Apligraf, which was determined subjectively, decreased over time. This was partially attributed to the inability of the investigators to determine whether allograft had replaced the patient's skin or whether the patient's skin had replaced the allograft. The possible occurrence of silent rejection (i.e., the replacement of the allograft by host tissue) indicates a

Cellular and/or Tissue-based Products (CTP), continued

need for additional studies to evaluate this phenomenon at the cellular level in order to fully resolve questions about graft take and rejection.

Biobrane/Biobrane-L: Two studies, one large uncontrolled study and one small, randomized study, demonstrated significantly reduced pain and shorter hospital stay in pediatric patients with scald burn wounds. The larger, uncontrolled trial, however, failed to delineate outcome measures and procedures related to methodology. Researchers did not provide clear measurement of pain assessment and compelling comparisons of hospital length of stay. Also, in patients with deep partial-thickness burns, the rate of infection was significantly higher than the rate of infection in patients with superficial partial-thickness burns. Further research is needed to explore the limited resistance of infection in more severely burned patients treated with Biobrane/Biobrane-L.

Dermagraft: The evidence regarding the efficacy of Dermagraft for treatment of diabetic foot ulcers is relatively good, although limited. Two randomized controlled trials, one of which involved 50 patients and the other of which included over 300 patients, both reported faster and more complete healing of chronic diabetic foot ulcers, compared with standard treatment. Additional study is required to define further patient selection criteria for Dermagraft, particularly with regards to ulcer duration and location.

EpiFix: One systematic review and 10 primary studies published between 2012 to 2014, demonstrated EpiFix to be of similar efficacy and safety as alternative substitutes. The published studies identified no significant safety issues such as aberrant tissue reactions or other issues. The studies demonstrate efficacy comparable if not potentially superior to some other graft materials. Limitations to any conclusions regarding the comparative efficacy of these therapies stems from a lack of comparative trials of various skin substitutes.

Several EpiFix studies attempted to provide comparative effectiveness to commonly used skin substitutes, Dermagraft and Apligraf. The studies suggest EpiFix has better 12-week closure rates than either Dermagraft or Apligraf as well as lower ulcer recurrence rates.

The important question of how EpiFix compares to Apligraf and dressings was addressed by Zelen et al. in a 2014 study of 60 patients. EpiFix improved outcomes significantly more than the Apligraf and dressings group. This was the only study to compare these three treatments. The literature on EpiFix, overall, is favorable related to outcomes though there exists a lack of comparative studies for most alternative skin substitutes. It is important to note, however, that all the literature is published by the manufacturer which may bias some of the outcomes. Current evidence, however, suggests EpiFix improves outcomes above-and-beyond standard dressings and conventional allografts.

Integra: Evidence regarding the efficacy of Integra for treatment of acute burn wounds is relatively weak. Results of a randomized, matched-pair comparison trial suggested that Integra provided a permanent cover that was at least as satisfactory as other skin graft techniques, with less hypertrophic scarring than control grafts. However, infection was evident in several patients. In a more recent but smaller randomized trial, Integra demonstrated poor resistance to infection, and the trial was prematurely terminated due to deaths attributable to infection. Results of a retrospective study and a prospective uncontrolled trial suggested that the use of Integra was safe and effective in patients with acute burns and was associated with decreased hospital stay; however, both studies lacked blinding, randomization, and adequate study populations.

Evidence for the use of Integra template for reconstructive surgery is limited and currently includes only case series studies. These uncontrolled studies demonstrated positive outcomes with Integra use, such as substantial minimization of postoperative contracture and good aesthetic and functional outcomes. Patient and physician satisfaction ranked high, although these subjective outcomes were not fully analyzed for reliability.

OrCel: Only 1 randomized trial evaluating OrCel was available in the literature. This study compared OrCel with Biobrane-L for donor site wounds in patients who were undergoing skin grafting for acute burn injuries. The study found that OrCel stimulated greater skin regeneration and wound healing, and less scarring, compared with Biobrane-L.

TransCyte/Dermagraft-TC: Three small, randomized controlled studies reported on the safety and efficacy of TransCyte/ Dermagraft-TC in treating patients with moderate to deep partial-thickness burn wounds. These studies provided some evidence that TransCyte was effective in reducing pain, with an increased rate of re-epithelialization in serious burn wounds; however, results were limited by small study

Cellular and/or Tissue-based Products (CTP), continued

populations and short follow-up periods. Complications attributed to the use of skin substitute products were relatively rare in the literature; infection was the most frequently reported complication, although in most studies, wound infection occurred at a comparable rate in patients treated with standard therapy alone.

Definitive patient selection criteria for the use of skin substitutes for wound healing have not been established. However, there is sufficient evidence to conclude that the use of Apligraf combined with standard wound care can improve healing in patients with chronic venous and diabetic foot ulcers. There is also sufficient evidence to support the use of Dermagraft in patients with chronic diabetic foot ulcers. These conclusions assume that patients have had an inadequate response to appropriate standard wound therapy. The use of skin substitutes is contraindicated in patients with evidence of arterial occlusive disease, i.e., ankle-brachial index (ABI) > 0.65, infection in ulcer(s) targeted for treatment, exudate consistent with heavy bacterial contamination, or eschar or necrotic tissue that would interfere with graft take and healing, active Charcot's disease, or hypersensitivity or allergy to any components of the skin substitute product or packaging medium. The efficacy and safety of skin substitutes in patients who are pregnant or lactating, have uncontrolled diabetes, or are currently being treated with corticosteroids, immunosuppressants, or chemotherapy have not been established.

Billing/Coding Information

CPT CODES

Covered: For the conditions outlined above

15271	Application of skin substitute graft to trunk, arms, legs, total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area
15272	; 100 sq cm; each additional 25 sq cm wound surface area, or part thereof (List separately in addition to code for primary procedure)
15273	; greater than or equal to 100 sq cm; first 100 sq cm wound surface area, or 1% of body area of infants and children
15274	; greater than or equal to 100 sq cm; each additional 100 sq cm wound surface area, or part thereof, or each additional 1% of body area of infants and children, or part thereof (List separately in addition to code for primary procedure)
15275	Application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area
15276	; each additional 25 sq cm wound surface area, or part thereof (List separately in addition to code for primary procedure)
15277	; greater than or equal to 100 sq cm; first 100 sq cm wound surface area, or 1% of body area of infants and children
15278	; greater than or equal to 100 sq cm; each additional 100 sq cm wound surface area, or part thereof, or each additional 1% of body area of infants and children, or part thereof (List separately in addition to code for primary procedure)

Repair of anorectal fistula with plug (e.g., Biodesign (Surgisis) AFP Anal Fistula Plug, GORE BIO-A Fistula Plug)

46707	Repair of anorectal fistula with plug (e.g.: porcine small intestine submucosa [SIS])
--------------	---

HCPCS CODES

A2001	Innovamatrix AC, per sq cm
A2007	Restrata, per sq cm
A2013	Innovamatrix FS, per sq cm

Cellular and/or Tissue-based Products (CTP), continued

A2026	Restrata minimatrix, 5 mg
C1781	Mesh (Implantable) – (ie, Davol Synthetic Mesh, AlloMax™ Surgical Graft, Phasix™ Mesh, Phasix™ ST Mesh, XenMatrix™ Surgical Graft and XenMatrix™ AB Surgical Graft)
C5271	Application of low cost skin substitute graft to trunk, arms, legs, total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area
C5272	; each additional 25 sq cm wound surface area, or part thereof (list separately in addition to code for primary procedure)
C5273	; greater than or equal to 100 sq cm; first 100 sq cm wound surface area, or 1% of body area of infants and children
C5274	; greater than or equal to 100 sq cm; each additional 100 sq cm wound surface area, or part thereof, or each additional 1% of body area of infants and children, or part thereof (list separately in addition to code for primary procedure)
C5275	Application of low cost skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area
C5276	; each additional 25 sq cm wound surface area, or part thereof (list separately in addition to code for primary procedure)
C5277	Application of low cost skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area greater than or equal to 100 sq cm; first 100 sq cm wound surface area, or 1% of body area of infants and children
C5278	; each additional 100 sq cm wound surface area, or part thereof, or each additional 1% of body area of infants and children, or part thereof (list separately in addition to code for primary procedure)
Q4100	Skin substitute, not otherwise specified
Q4101	Apligraf, per sq cm
Q4102	Oasis wound matrix, per sq cm
Q4103	Oasis burn matrix, per sq cm
Q4104	Integra bilayer matrix wound dressing (BMWD), per sq cm
Q4105	Integra dermal regeneration template (DRT) or Integra Omnigraft dermal regeneration matrix, per sq cm
Q4106	Dermagraft, per sq cm
Q4107	GRAFTJACKET, per sq cm
Q4108	Integra matrix, per sq cm
Q4110	PriMatrix, per sq cm
Q4111	GammaGraft, per sq cm
Q4112	Cymetra, injectable, 1 cc
Q4113	GRAFTJACKET XPRESS, injectable, 1cc
Q4114	Integra flowable wound matrix, injectable, 1 cc
Q4115	AlloSkin, per sq cm

Cellular and/or Tissue-based Products (CTP), continued

Q4116	AlloDerm, per sq cm
Q4117	HYALOMATRIX, per sq cm
Q4118	MatriStem micromatrix, 1 mg
Q4121	TheraSkin, per sq cm
Q4122	DermACELL, per sq cm
Q4123	AlloSkin RT, per sq cm
Q4124	OASIS ultra tri-layer wound matrix, per sq cm
Q4125	Arthroflex, per sq cm
Q4126	MemoDerm, DermaSpan, TranZgraft or InteguPly, per sq cm
Q4127	Talymed, per sq cm
Q4128	FlexHD, AllopatchHD, or Matrix HD, per sq cm
Q4132	Grafix core, per sq cm
Q4133	Grafix prime, per sq cm
Q4141	Alloskin AC, per sq cm
Q4166	Cytal, per sq cm
Q4186	Epifix, per sq cm
Q4208	Novafix, per sq cm
Q4254	Novafix DL, per sq cm

Key References

1. AHRQ. Skin Substitutes for Treating Chronic Wounds. 2012 December 18, 2012 [cited 2015 February 20].
2. Allenet B, Paree F, Lebrun T, et al. (200). Cost-effectiveness modeling of Dermagraft for the treatment of diabetic foot ulcers in the french context. *Diabetes Metab. Apr*;26(2):125-32.
3. Armstrong, D.G. Clinical assesment of wounds. 2014 August 6, 2013 [cited 2014 October 31]; Available from: http://www.uptodate.com/contents/clinical-assessment-of-wounds?source=search_result&search=skin+wounds&selectedTitle=2~150.
4. Armstrong, D.G. Basic Principles of Wound Management. 2014 January 28, 2014 [cited 2014 November 11]; Available from: http://www.uptodate.com/contents/basic-principles-of-wound-management?source=search_result&search=wound+management&selectedTitle=1~150.
5. European Pressure Ulcer Advisory Panel. Prevention and Treatment of Pressure Ulcers: Quick Reference Guide. 2004. [cited 2014 November 11]; Available from: <http://www.epuap.org/wp-content/uploads/2010/10/Quick-Reference-Guide-DIGITAL-NPUAP-EPUAP-PPPIA-16Oct2014.pdf>.
6. Fetterolf, D.E., Scientific and Clinical Support for the Use of Dehydrated Amniotic Membrane in Wound Management. *Wounds*, 2012. 24(10): p. 299-307.
7. Fetterolf, D.E., N.B. Istwan, and G.J. Stanziano, An evaluation of healing metrics associated with commonly used advanced wound care products for the treatment of chronic diabetic foot ulcers. *Manag Care*, 2014. 23(7): p. 31-8.
8. Fivenson D, Scherschun L. (2003). Clinical and economic impact of Apligraf for the treatment of nonhealing venous leg ulcers. *Int J Dermatol. Dec*;42(12):960-5.
9. Forbes, J. and D.E. Fetterolf, Dehydrated amniotic membrane allografts for the treatment of chronic wounds: a case series. *J Wound Care*, 2012. 21(6): p. 290, 292, 294-6.
10. Koob, T.J., et al., Properties of dehydrated human amnion/chorion composite grafts: Implications for wound repair and soft tissue regeneration. *J Biomed Mater Res B Appl Biomater*, 2014.
11. Koob, T.J., et al., Angiogenic properties of dehydrated human amnion/chorion allografts: therapeutic potential for soft tissue repair and regeneration. *Vasc Cell*, 2014. 6: p. 10.
12. Koob, T.J., et al., Biological properties of dehydrated human amnion/chorion composite graft: implications for chronic wound healing. *Int Wound J*, 2013. 10(5): p. 493-500.
13. Medical Technology Directory. (2010). Biosynthetic Tissue-Engineered Skin Substitutes for Wound Healing. Winifred S. Hayes, Inc. Jan 14.
14. MiMedx. EpiFix. 2014. [cited 2014 June 30]; Available from: http://mimedx.com/products?qt-product_tabs=4#qt-product_tabs.
15. Serena, T.E., et al., A Multi-center Randomized Controlled Clinical Trial Evaluating the Use of Dehydrated Human Amnion/Chorion Membrane Allografts and Multi-layer Compression Therapy vs. Multi-layer Compression Therapy Alone in the Treatment of Venous Leg Ulcers. *Wound Repair Regen*, 2014.
16. Sheikh, E.S., E.S. Sheikh, and D.E. Fetterolf, Use of dehydrated human amniotic membrane allografts to promote healing in patients with refractory non healing wounds. *Int Wound J*, 2013.

Cellular and/or Tissue-based Products (CTP), continued

17. Source, W. EpiFix Amniotic Membrane Allograft. 2014. [cited 2014 July 3]; Available from: <http://www.woundsource.com/product/EpiFix-amniotic-membrane-allograft>.
18. The Wound Healing Society. Chronic Wound Care Guidelines. 2007. [cited 2014 November 11]; Available from: http://woundheal.org/documents/final_pocket_guide_treatment.aspx.
19. Zelen, C.M., An evaluation of dehydrated human amniotic membrane allografts in patients with DFUs. J Wound Care, 2013. 22(7): p. 347-8, 350-1.
20. Zelen, C.M., T.E. Serena, and D.E. Fetterolf, Dehydrated human amnion/chorion membrane allografts in patients with chronic diabetic foot ulcers: A long-term follow-up study. Wound Medicine, 2014. 4(0): p. 1-4.
21. Zelen, C.M., et al., A prospective randomised comparative parallel study of amniotic membrane wound graft in the management of diabetic foot ulcers. Int Wound J, 2013. 10(5): p. 502-7.
22. Zelen, C.M., et al., A prospective, randomised, controlled, multi-centre comparative effectiveness study of healing using dehydrated human amnion/chorion membrane allograft, bioengineered skin substitute or standard of care for treatment of chronic lower extremity diabetic ulcers. Int Wound J, 2014.

Revision History

Revision Date	Summary of Changes
4/7/23	For Commercial Plan Policy, removed Flower AmnioPatch from the list of eligible synthetic skin substitutes available for coverage, and added Innovamatrix and Restrata to the list of eligible synthetic skin substitutes available for coverage.

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate healthcare providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Select Health® makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. Select Health updates its Coverage Policies regularly, and reserves the right to amend these policies without notice to healthcare providers or Select Health members.

Members may contact Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Coverage Policy may call Select Health Provider Relations at (801) 442-3692.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Select Health.

"Intermountain Healthcare" and its accompanying logo, the marks of "Select Health" and its accompanying marks are protected and registered trademarks of the provider of this Service and or Intermountain Health Care, Inc., IHC Health Services, Inc., and Select Health, Inc. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association



MEDICAL POLICY

THERAPY FOR HYPERTROPHIC/KELOID SCARS

Policy # 231

Implementation Date: 6/10/04

Review Dates: 8/25/05, 8/17/06, 8/23/07, 8/21/08, 8/13/09, 8/19/10, 9/15/11, 11/29/12, 10/24/13, 10/23/14, 10/15/15, 10/20/16, 10/19/17, 10/1/18, 10/15/19, 10/15/20, 11/17/21, 9/14/22, 10/13/23, 10/8/24

Revision Dates: 8/28/06, 5/10/16, 12/30/19, 8/15/23, 11/6/23, 3/20/24

Related Medical Policies:

[#103 Benign Skin and Subcutaneous Lesions](#)**Disclaimer:**

1. Policies are subject to change without notice.
2. Policies outline coverage determinations for Select Health Commercial, Select Health Advantage (Medicare/CMS), and Select Health Community Care (Medicaid/CHIP) plans. Refer to the "Policy" section for more information.

Description

Keloids are benign fibrous growths that arise from proliferation of dermal tissue following skin injury. Keloids are common (keloids develop in 5%–15% of wounds). Conventional treatment options for keloids are occlusive dressings (including silicone-based materials), compression therapy, intralesional injections of corticosteroid, cryosurgery, and excision surgery. Newer modalities include the carbon dioxide, Nd:YAG, argon lasers, pulsed dye laser, intralesional interferon-gamma and interferon-alfa 2b, as well as cultured epithelial autografts. The incidence of recurrence is rather high following conventional forms of treatment. In particular, the recurrence rate of keloids after excision alone has been reported to be between 45%–100%. It has also been found that the recurrence rate following excision is higher with keloids forming at infected sites and in patients with a family history. Moreover, there is no increased likelihood of recurrence with respect to patient age, sex, or ethnicity; or keloid size or location, individual keloid history, or prior therapy used (in general, various lasers have produced similar recurrence rates as conventional surgery).

The pulsed dye laser delivers energy at a wavelength and duration that has been optimized for the selective treatment of vascular lesions. It has been used in the treatment of warts, port-wine stains, hemangiomas, hypertrophic scars, keloid scars, and telangiectasias. Pulsed dye lasers have been used as an alternative to surgical excision or carbon dioxide lasers. The Food and Drug Administration (FDA) has cleared the pulsed-dye laser for use in treatment of warts, port-wine stains, hemangiomas, hypertrophic scars, keloid scars, and telangiectasias.

COMMERCIAL PLAN POLICY AND CHIP (CHILDREN'S HEALTH INSURANCE PROGRAM)

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request.

Select Health may cover superficial radiation therapy of symptomatic keloids following excisional surgery, when the patient has failed conservative therapy*; fraction standards are as follows: 18–19 Gy in 3 fractions (earlobe) or 23–25 Gy in 3 fractions (non-earlobe).

Select Health covers laser therapy for the treatment of symptomatic hypertrophic or keloid scars in *limited circumstances* for patients who have failed conservative therapy*.

*Conservative therapy should include at least a 3-month trial of one of the following:

- a) Corticosteroid tape or plaster
- b) Corticosteroid injection

Laser Therapy for Keloids and Hypertrophic Scars, continued

- c) Topical steroid ointment or cream
- d) 5-fluorouracil intralesional steroid injections
- e) Cryotherapy

Select Health does NOT cover intralesional interferon alfa injections for the treatment of hypertrophic or keloid scars as available evidence for the efficacy of this therapy is weak and conflicting. This treatment meets the plan's definition of experimental/investigational.

SELECT HEALTH MEDICARE

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the Select Health Commercial policy applies. For the most up-to-date Medicare policies and coverage, please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp&> or the manual website

SELECT HEALTH COMMUNITY CARE (MEDICAID)

Coverage is determined by the State of Utah Medicaid program; if Utah State Medicaid has no published coverage position and InterQual criteria are not available, the Select Health Commercial criteria will apply. For the most up-to-date Medicaid policies and coverage, please visit their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Summary of Medical Information

The precise pathogenesis of keloid formation is unknown. For some reason, certain individuals, most commonly African Americans and other ethnicities with darker skin tones, develop a hyperproliferation of fibroblasts in response to trauma, or, less commonly, de novo. Any skin insult (e.g., ear piercing, lacerations, secondarily infected skin lesions, acne, surgery, etc.) can cause keloid formation in predisposed individuals.

Alteration of apoptosis (programmed cell death) and cell proliferation have been implicated in the pathogenesis of keloids. In one study that compared the expression of 64 apoptosis-related genes in keloids and normal scars, under-expression of 8 of these genes was found in the fibroblasts derived from keloid tissue. The authors suggested that keloid fibroblasts fail to undergo physiologically programmed cell death, and therefore, continue to produce connective tissue beyond the period expected for normal scars. Others have come to similar conclusions. Overactivation of signals for insulin-like growth factor-I have also been implicated in the pathogenesis of keloids.

The diagnosis is based upon the clinical appearance of excessive scar tissue. Patients may be asymptomatic, but frequently have lesions that are pruritic, tender to palpation, or a source of sharp, shooting pains. Most commonly keloids occur on the ears, neck, jaw, presternal chest, shoulder girdle area, but can occur in any location, particularly in predisposed individuals. Another clinic example of a dermatologic condition leading to keloid formation is acne keloidalis nuchae, which refers to inflamed pustules and papules on the posterior neck that often heal with keloid formation.

Hypertrophic scars may initially appear similar to keloids, but in contrast to the latter, hypertrophic scars do not extend beyond the margins of the original skin injury or insult. While the treatment strategies are similar for both lesions, hypertrophic scars are less likely to recur once treated.

The best treatment is prevention in patients with a known predisposition. This includes preventing unnecessary trauma or surgery (including ear piercing, elective mole removal), whenever possible. Any skin problems in predisposed individuals (e.g., acne, infections) should be treated as early as possible to minimize areas of inflammation and subsequent scarring. Patients who have acne keloidalis nuchae should avoid shaving in the neck region, and the posterior hair should only be trimmed with scissors and trimmed no shorter than 1/8 inch.

Laser Therapy for Keloids and Hypertrophic Scars, continued

Several treatment options are available for keloids that are painful or cosmetically disfiguring. Combinations of these therapies are also effective. Patients should be advised, however, that recurrences are possible despite therapy. The earlier keloids are treated, the more likely it is that they will respond to therapy.

Intralesional corticosteroids are first-line therapy for most keloids. A systematic review found that up to 70% of patients respond to intralesional corticosteroid injection with flattening of keloids, although the recurrence rate is high in some studies (up to 50% at 5 years). Lipoatrophy may occur if the injections are done below the scar rather than in the scar. Injections can be repeated at monthly intervals, increasing the concentration of triamcinolone by 10 mg/mL on non-facial lesions until the lesion softens and flattens, then decreasing the frequency and strength of injections. Doses should not exceed 40 mg of the drug per visit; atrophy and hypopigmentation may occur at higher doses. Surgical excision is recommended if there is no response after four injections.

Silicone gel sheeting is effective in established keloids for reducing associated symptoms (e.g., pain and itching), but is most useful for preventing and managing evolving keloids in new sites of injury. In one study, for example, silicone gel sheeting was placed over evolving scars in 20 patients, with the dressing worn for at least 12 hours per day. Lesions improved during the treatment period in 85% of cases. The mechanism by which silicone gel sheeting exerts an anti-scarring effect is unknown but may be related to generation of static electricity.

Silicone gel sheeting and silicone gel are available by prescription and over-the-counter. The sheeting is clear and sticky and should be cut to fit the size of the keloid. The sheeting is placed on top of the keloid, taped into place, and left on for 12–24 hours per day. The sheet is washed daily and replaced every 10 to 14 days. Effectiveness is judged after 2–6 months of therapy.

Pressure therapy is usually performed with pressure garments, bandages, or special devices for certain locations such as the ear. A type of pressure earrings for earlobe keloids called Zimmer splints can be molded to the appropriate size and cosmetically altered to appear as earrings. Other devices using magnets with or without silicone sheeting have also been used as post-surgery adjuvant therapy for ear keloids.

The mechanism of action of pressure may involve the reduction of oxygen tension in the wound through the occlusion of small blood vessels, resulting in a decreased fibroblast proliferation and collagen synthesis. However, the optimal amount of pressure is difficult to determine. It should exceed the inherent capillary pressure without diminishing the peripheral blood circulation (20 to 30 mmHg). In one study, the applied pressure was 35 mmHg, which was estimated using a digital manometer.

The evidence to support the use of pressure therapy is limited. A 2009 meta-analysis of six high quality randomized trials including 316 burn patients did not demonstrate a difference in the global scar assessment between patients treated with pressure garments and untreated patients. Observational studies of patients with ear keloids have shown that custom-made pressure devices may be beneficial to reduce the risk of recurrence after surgical excision.

Surgical excision of hypertrophic scars and keloids may be indicated if conservative therapies alone are unsuccessful or unlikely to result in significant improvement. Surgical excision of keloids is associated with recurrence rates of up to 100 percent. The combination of surgery with adjunctive perioperative therapies can significantly lower the risk of recurrence. Surgical excision combined with preoperative, intraoperative, and postoperative intralesional injection triamcinolone acetonide has been reported in several small, uncontrolled studies using various dosages, schedules and concentrations of the drug.

In one study, 80 patients with keloids of one- to four-year duration underwent surgical excision followed by a single injection of 5-FU and botulinum toxin eight days post-surgery. Recurrence occurred in three (4 percent) patients after a follow-up time of 17 to 24 months.

Surgical excision followed by immediate freezing of the open wound was performed in one study of 66 patients with 97 large ear keloids. After a median follow-up time of 12 months, 36 percent of lesions recurred and required further treatment.

A few small observational studies have reported that postoperative use of imiquimod with daily or alternate day applications may reduce the rate of recurrence of keloids. However, other studies have provided conflicting results.

Laser Therapy for Keloids and Hypertrophic Scars, continued

Several studies have found radiation therapy to be highly effective in reducing keloid recurrence when administered immediately after surgical excision. A variety of techniques, doses, and schedules of radiation have been used in the treatment of keloids. These include megavoltage external beam radiation therapy, lower energy external radiation sources (radiographs, Co-60), electron beam, and various brachytherapy techniques. Reviews of the literature have found that the effectiveness in preventing recurrence is related to the biologically effective dose (BED) and is influenced by the site of the keloid. As an example, one report found that recurrence of keloids in the earlobe could be prevented in 90 percent of cases with a dose of approximately 16 Gy, given in three fractions using electron beam techniques. A second review reached a similar conclusion, with a BED of about 30 Gy reducing the recurrence rate to < 10 percent.

Concerns regarding the potential long-term risks associated with the use of radiation therapy limit its utilization for these lesions. Several cases of malignancy that may have been associated with radiation therapy for keloids have been reported. Although causation cannot be confirmed in these cases, caution should still be used when prescribing adjuvant radiation therapy for keloids, particularly when treating younger patients.

Radiation therapy may occasionally be indicated for lesions that are not amenable to resection.

Cryosurgery is most useful in combination with other treatments for keloids, although up to 50% of patients may respond to cryotherapy alone. The major side effect is permanent hypopigmentation, limiting its use in patients with darker skin. A 10–30 second freeze-thaw cycle is used and can be repeated up to three times per treatment session. Therapy is repeated once per month until response occurs.

Interferon alfa injections may reduce recurrence rates postoperatively. However, all currently available studies of interferon therapy suffer from methodologic problems, making an evidence-based recommendation regarding its use difficult.

Billing/Coding Information

CPT CODES

11900	Injection, intralesional; up to and including seven lesions
11901	Injection, intralesional; more than 7 lesions
17000	Destruction (e.g., laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), premalignant lesions (e.g., actinic keratoses); first lesion
17003	; second through 14 lesions, each (List separately in addition to code for first lesion)
17004	; 15 or more lesions
17106	Destruction of cutaneous vascular proliferative lesions (e.g., laser technique); less than 10 sq cm
17107	; 10.0 - 50.0 sq cm
17108	; over 50.0 sq cm

HCPCS CODES

J3301	Injection, triamcinolone acetonide, not otherwise specified, 10 mg
J3302	Injection, triamcinolone diacetate, per 5 mg
J9040	Injection, bleomycin sulfate, 15 units

Key References

1. Alster, TS, Williams, CM. Treatment of keloid sternotomy scars with 585 nm flashlamp-pumped pulsed-dye laser. Lancet 1995; 345:1198.
2. Alster T. Laser scar revision: Comparison study of 585-nm pulsed dye laser with and without intralesional corticosteroids. Dermatol Surg. 2003;29(1):25-29.
3. Alster TS. Laser treatment of hypertrophic scars, keloids, and striae. Dermatol Clin. 1997;15(3):419-429.

Laser Therapy for Keloids and Hypertrophic Scars, continued

4. Anzarut A, Olson J, Singh P, et al. The effectiveness of pressure garment therapy for the prevention of abnormal scarring after burn injury: a meta-analysis. *J Plast Reconstr Aesthet Surg* 2009; 62:77.
5. Bao Y, Xu Z, Pan Z, et al. Comparative efficacy and safety of common therapies in keloids and hypertrophic scars: A systematic review and meta-analysis. *Aesthetic Plast Surg*. 2020;44(1):207-218.
6. Berman B, Flores F. The treatment of hypertrophic scars and keloids. *Eur J Dermatol*. 1998;8(8):591-595.
7. Berman, B, Bielek, HC. Adjunct therapies to surgical management of keloids. *Dermatol Surg* 1996; 22:126.
8. Berman, B, Kaufman J. Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids.
9. Berman, B, Flores, F. Comparison of a silicone gel-filled cushion and silicon gel sheeting for the treatment of hypertrophic or keloid scars. *Dermatol Surg* 1999; 25:484.
10. Berman B, Harrison-Balestra C, Perez OA, et al. Treatment of keloid scars post-shave excision with imiquimod 5% cream: A prospective, double-blind, placebo-controlled pilot study. *J Drugs Dermatol* 2009; 8:455.
11. Berman B, Flores F. Recurrence rates of excised keloids treated with postoperative triamcinolone acetonide injections or interferon alfa-2b injections. *J Am Acad Dermatol* 1997; 37:755.
12. Bijlard, E., Steltenpool, S., & Niessen, F.B. (2015). Intralesional 5-fluorouracil in keloid treatment: a systematic review. *Acta Derm Venereol*. 95(7): 778. doi: 10.2340/00015555-2106
13. Botwood N, Lewanski C, Lowdell C. The risks of treating keloids with radiotherapy. *Br J Radiol* 1999; 72:1222.
14. Bran GM, Brom J, Hörmann K, Stuck BA. Auricular keloids: combined therapy with a new pressure device. *Arch Facial Plast Surg* 2012; 14:20.
15. Cação FM, Tanaka V, Messina MC. Failure of imiquimod 5% cream to prevent recurrence of surgically excised trunk keloids. *Dermatol Surg* 2009; 35:629.
16. Chuangsuwanich A, Gunjittisomram S. The efficacy of 5% imiquimod cream in the prevention of recurrence of excised keloids. *J Med Assoc Thai* 2007; 90:1363.
17. De Cicco L, Vischioni B, Vavassori A, et al. Postoperative management of keloids: low-dose-rate and high-dose-rate brachytherapy. *Brachytherapy* 2014; 13:508.
18. Emad M, Omidvari S, Dastgheib L, et al. Surgical excision and immediate postoperative radiotherapy versus cryotherapy and intralesional steroids in the management of keloids: a prospective clinical trial. *Med Princ Pract* 2010; 19:402.
19. English RS, Shenefelt PD. Keloids and hypertrophic scars. *Dermatol Surg*. 1999;25(8):631-638.
20. Flickinger JC. A radiobiological analysis of multicenter data for postoperative keloid radiotherapy. *Int J Radiat Oncol Biol Phys* 2011; 79:1164.
21. Fulton, JE Jr. Silicone gel sheeting for the prevention and management of evolving hypertrophic and keloid scars. *Dermatol Surg* 1995; 21:947.
22. Gold, M.H., Berman, B, Clementoni, M.T., Gauglitz, G.G., Nahai, F., & Murcia, C. (2014). Updated international clinical recommendations on scar management: part 1—evaluating the evidence. *Dermatol Surg*. 40(8): 817. doi: 10.1111/dsu.0000000000000049
23. Gold, MH. Topical silicone gel sheeting in the treatment of hypertrophic scars and keloids. A dermatologic experience. *J Dermatol Surg Oncol* 1993; 19:912.
24. Goldenberg G, Luber AJ. Use of intralesional cryosurgery as an innovative therapy for keloid scars and a review of current treatments. *J Clin Aesthet Dermatol* 2013; 6:23.
25. Hamrick M, Boswell W, Carney D. Successful treatment of earlobe keloids in the pediatric population. *J Pediatr Surg* 2009; 44:286.
26. Har-Shai Y, Sabo E, Rohde E, et al. Intralesional cryosurgery enhances the involution of recalcitrant auricular keloids: a new clinical approach supported by experimental studies. *Wound Repair Regen* 2006; 14:18.
27. Har-Shai Y, Dujovny E, Rohde E, Zouboulis CC. Effect of skin surface temperature on skin pigmentation during contact and intralesional cryosurgery of keloids. *J Eur Acad Dermatol Venereol* 2007; 21:191.
28. Hirshowitz, B, Lerner, D, Moscona, AR. Treatment of keloid scars by combined cryosurgery and intralesional corticosteroids. *Aesthetic Plast Surg* 1982; 6:153.
29. Hirshowitz, B, Lindenbaum, E, Har-Shai, Y, et al. Static-electric field induction by a silicone cushion for the treatment of hypertrophic and keloid scars. *Plast Reconstr Surg* 1998; 101:1173.
30. Jung JY, Roh MR, Kwon YS, Chung KY. Surgery and perioperative intralesional corticosteroid injection for treating earlobe keloids: a Korean experience. *Ann Dermatol* 2009; 21:221.
31. Kal HB, Veen RE, Jürgenliemk-Schulz IM. Dose-effect relationships for recurrence of keloid and pterygium after surgery and radiotherapy. *Int J Radiat Oncol Biol Phys* 2009; 74:245.
32. Kiil J. Keloids treated with topical injections of triamcinolone acetonide (kenalog). Immediate and long-term results. *Scand J Plast Reconstr Surg* 1977; 11:169.
33. Kim J, Lee SH. Therapeutic results and safety of postoperative radiotherapy for keloid after repeated Cesarean section in immediate postpartum period. *Radiat Oncol J* 2012; 30:49.
34. Klumppar, DI, Murray, JC, Anscher, M. Keloids treated with excision followed by radiation therapy. *J Am Acad Dermatol* 1994; 31:225.
35. Lee SY, Park J. Postoperative electron beam radiotherapy for keloids: treatment outcome and factors associated with occurrence and recurrence. *Ann Dermatol* 2015; 27:53.
36. Lee, J. W., & Seol, K. H. Adjuvant Radiotherapy after Surgical Excision in Keloids. *Medicina*, 2021, 57, 730. <https://doi.org/10.3390/medicina57070730>
37. Litrowski N, Boullie MC, Dehesdin D, et al. Treatment of earlobe keloids by surgical excision and cryosurgery. *J Eur Acad Dermatol Venereol* 2014; 28:1324.
38. Malaker K, Vijayraghavan K, Hodson I, Al Yafi T. Retrospective analysis of treatment of unresectable keloids with primary radiation over 25 years. *Clin Oncol (R Coll Radiol)* 2004; 16:290.
39. Nemeth, AJ. Keloids and hypertrophic scars. *J Dermatol Surg Oncol* 1993; 19:738.
40. Ogawa R, Yoshitatsu S, Yoshida K, Miyashita T. Is radiation therapy for keloids acceptable? The risk of radiation-induced carcinogenesis. *Plast Reconstr Surg* 2009; 124:1196.
41. Ogawa R, Huang C, Akaishi S, et al. Analysis of surgical treatments for earlobe keloids: analysis of 174 lesions in 145 patients. *Plast Reconstr Surg* 2013; 132:818e.

Laser Therapy for Keloids and Hypertrophic Scars, continued

42. Ogawa R, Akita S, Akaishi S, et al. Diagnosis and Treatment of Keloids and Hypertrophic Scars-Japan Scar Workshop Consensus Document 2018. *Burns Trauma*. 2019Dec 27; 7:39. doi: 10.1186/s41038-019-0175-y. PMID: 31890718; PMCID: PMC6933735.
43. Ogawa R. The Most Current Algorithms for the Treatment and Prevention of Hypertrophic Scars and Keloids: A 2020 Update of the Algorithms Published 10 Years Ago. *Plast Reconstr Surg*. 2022 Jan 1;149(1):79e-94e. doi: 10.1097/PRS.0000000000008667. PMID: 34813576; PMCID: PMC8687618.
44. Ohtsuru, A, Yoshimoto, H, Ishihara, H, et al. Insulin-like growth factor-I (IGF-I)/IGF-I receptor axis and increased invasion activity of fibroblasts in keloid [In Process Citation]. *Endocr J* 2000; 47 Suppl: S41.
45. Park TH, Seo SW, Kim JK, Chang CH. Outcomes of surgical excision with pressure therapy using magnets and identification of risk factors for recurrent keloids. *Plast Reconstr Surg* 2011; 128:431.
46. Park TH. New pressure device, "Magsil," as an adjuvant pressure therapy for ear keloids. *Arch Facial Plast Surg* 2012; 14:298.
47. Park TH, Park JH, Kim JK, et al. Analysis of 15 cases of auricular keloids following conchal cartilage grafts in an asian population. *Aesthetic Plast Surg* 2013; 37:102.
48. Porter JP. Treatment of the keloid. What's new? *Otolaryngol Clin North Am*. 2002;35(1):207-220, viii.
49. Quintal EJ. Keloids. In: Conn's Current Therapy. 54th Ed. RE Rakel, ET Bope, eds. Philadelphia, PA: W.B. Saunders Co.; 2002:798-801.
50. Ragoowansi R, Comes PG, Moss AL, Glees JP. Treatment of keloids by surgical excision and immediate postoperative single-fraction radiotherapy. *Plast Reconstr Surg* 2003; 111:1853.
51. Rusciari L, Paradisi A, Alfano C, et al. Cryotherapy in the treatment of keloids. *J Drugs Dermatol* 2006; 5:591.
52. Russell, R, Horlock, N, Gault, D. Zimmer splintage: a simple effective treatment for keloids following ear-piercing. *Br J Plast Surg* 2001; 54:509.
53. Sadeghinia, A., & Sadeghinia, S. (2012). Comparison of the efficacy of intralesional triamcinolone acetate and 5-fluorouracil tattooing for the treatment of keloids. *Dermatol Surg*. 38(1): 104–9. doi: 10.1111/j.1524-4725.2011.02137.x
54. Sawada Y, Sone K. Treatment of scars and keloids with a cream containing silicone oil. *Br J Plast Surg*. 1990;43(6):683-688.
55. Sayah, DN, Soo, C, Shaw, WW, et al. Downregulation of apoptosis-related genes in keloid tissue. *J Surg Res* 1999; 87:209.
56. Sclafani, AP, Gordon, L, Chadha, M, Romo, T 3rd. Prevention of earlobe keloid recurrence with postoperative corticosteroid injections versus radiation therapy: A randomized, prospective study and review of the literature. *Dermatol Surg* 1996; 22:569.
57. Shaffer JJ, Taylor SC, Cook-Bolden F. Keloidal scars: A review with a critical look at therapeutic options. *J Am Acad Dermatol*. 2002;46(2): S63-S97.
58. Shons AR, Press BH. The treatment of earlobe keloids by surgical excision and postoperative triamcinolone injection. *Ann Plast Surg* 1983; 10:480.
59. Sproat JE, Dalcin A, Weitauer N, Roberts RS. Hypertrophic sternal scars: silicone gel sheet versus Kenalog injection treatment. *Plast Reconstr Surg*. 1992;90(6):988-992.
60. Teofoli, P, Barduagni, S, Ribuffo, M, et al. Expression of Bcl-2, p53, c-jun and c-fos protooncogenes in keloids and hypertrophic scars. *J Dermatol Sci* 1999; 22:31.
61. Tying, S. Imiquimod applied topically: a novel immune response modifier [letter]. *Skin Therapy* 2001; 6:1.
62. van Leeuwen MC, Bulstra AE, van Leeuwen PA, Niessen FB. A new argon gas-based device for the treatment of keloid scars with the use of intralesional cryotherapy. *J Plast Reconstr Aesthet Surg* 2014; 67:1703.
63. van Leeuwen MC, van der Wal MB, Bulstra AE, et al. Intralesional cryotherapy for treatment of keloid scars: a prospective study. *Plast Reconstr Surg* 2015; 135:580.
64. van Leeuwen MC, Bulstra AE, Ket JC, et al. Intralesional Cryotherapy for the Treatment of Keloid Scars: Evaluating Effectiveness. *Plast Reconstr Surg Glob Open* 2015; 3: e437.
65. Viani GA, Stefano EJ, Afonso SL, De Fendi LI. Postoperative strontium-90 brachytherapy in the prevention of keloids: results and prognostic factors. *Int J Radiat Oncol Biol Phys* 2009; 73:1510.
66. Wagner, W, Alfrink, M, Micke, O, et al. Results of prophylactic irradiation in patients with resected keloids—a retrospective analysis. *Acta Oncol* 2000; 39:217.
67. Wang LZ, Ding JP, Yang MY, Chen B. Forty-five cases of chest keloids treated with subcutaneous super-tension-reduction suture combined with postoperative electron-beam irradiation. *Dermatol Surg* 2014; 40:1378.
68. Wilson AM. Eradication of keloids: Surgical excision followed by a single injection of intralesional 5-fluorouracil and botulinum toxin. *Can J Plast Surg* 2013; 21:87.
69. Zouboulis, CC, Blume, U, Buttner, P, Orfanos CE. Outcomes of cryosurgery in keloids and hypertrophic scars. A prospective consecutive trial of case series. *Arch Dermatol* 1993; 129:1146.

Revision History

Revision Date	Summary of Changes
11/6/23	For Commercial Plan Policy, modified first-line and second-line algorithms in criteria, as follows: "1. First-Line Therapy: A 3-month trial of steroid tape/plaster, or silicone gel sheeting/silastic sheeting, or other occlusive dressings and/or pressure therapy. 2. Second-Line Therapy: A 3-month trial of at least 3 separate injections of intralesional steroids or fluorouracil, given at monthly intervals, if not previously done."
3/20/24	Modified title of policy, and for Commercial Plan Policy, updated requirements for failure of conservative therapy and added coverage criteria for superficial radiation therapy of keloids.

Laser Therapy for Keloids and Hypertrophic Scars, continued

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate healthcare providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Select Health® makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. Select Health updates its Coverage Policies regularly, and reserves the right to amend these policies without notice to healthcare providers or Select Health members.

Members may contact Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Coverage Policy may call Select Health Provider Relations at (801) 442-3692.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Select Health.

"Intermountain Healthcare" and its accompanying logo, the marks of "Select Health" and its accompanying marks are protected and registered trademarks of the provider of this Service and or Intermountain Health Care, Inc., IHC Health Services, Inc., and Select Health, Inc. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association



MEDICAL POLICY

PULSED DYE LASER TREATMENT FOR DERMATOLOGICAL CONDITIONS

Policy # 168

Implementation Date: 7/98

Review Dates: 1/4/00, 12/25/00, 2/27/01, 6/5/02, 10/23/03, 11/18/04, 11/19/05, 12/21/06, 12/20/07, 12/18/08, 12/19/09, 10/21/10, 10/13/11, 11/29/12, 10/24/13, 10/23/14, 10/15/15, 10/20/16, 10/19/17, 10/1/18, 10/9/19, 10/10/20, 10/29/21, 9/13/22, 11/16/23, 10/3/24

Revision Dates: 10/2/17, 12/11/18, 10/24/19, 11/5/21, 6/1/22, 11/20/23, 10/17/24

Disclaimer:

1. Policies are subject to change without notice.
2. Policies outline coverage determinations for Select Health Commercial, Select Health Advantage (Medicare/CMS), and Select Health Community Care (Medicaid/CHIP) plans. Refer to the "Policy" section for more information.

Description

Port-wine birthmarks (PWB), are a congenital malformation, typically present as a well-demarcated bright or deep red macule or patch at birth (although some birthmarks are lighter in color when they initially present.) There are also acquired PWBs that have been described in adults. As patients with PWBs age, the capillary (blood vessel) malformation grows commensurately. The abnormal blood vessels within the PWB become progressively more dilated in size which results in the lesion becoming dark purple and elevated in some instances. Nodules and hypertrophy may develop in the soft tissue underlying the PWB. Nodules may continue to grow and begin to bleed easily if traumatized.

Common areas for PWB to appear are on the face, over the areas of the first and second trigeminal nerves, and the eyes or mouth. Also, it is not uncommon to see a birthmark overlying an arteriovenous, arterial or venous malformation. PWBs in these locations require the physician to look beyond the skin for many underlying problems, including but not limited to, leptomeningeal/brain and ocular anomalies. PWB in the absence of central nervous system involvement still have the distinction of persisting into adult life, disfiguring associated areas (being psychologically distressing), bleeding, ulcerating, becoming a source of infection, and leading to systemic abnormalities such as glaucoma.

Treatment of PWB in the macular/patch stages will prevent the development of the hypertrophic component of the lesion. Laser treatment of PWB diminishes the existing blood vessels making them smaller and fewer in number. Therefore, the progression of these lesions to a more advanced size is less likely to occur. Early and aggressive treatment may permit shorter and fewer treatment sessions. Treatment in children younger than 6 months of age has also been shown to be safe and effective.

Pulsed dye laser treatment has been shown to be beneficial for other vascular lesions not limited to rosacea-related papules and pustules, and skin sensitivity that has failed other treatments.

COMMERCIAL PLAN POLICY AND CHIP (CHILDREN'S HEALTH INSURANCE PROGRAM)

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request.

Select Health covers pulsed dye laser treatment in limited circumstances.

- A. For removal of port-wine birthmarks, one of the following criteria must be met:
1. Location on the genitals

Pulsed Dye Laser Treatment of Congenital Hemangiomas and Rosacea, continued

2. Location on the face
 3. Any port-wine birthmark area that compromises vital structures, that is symptomatic (e.g., crossing joints or other vital areas where mobility/function would be impaired without treatment, bleeding, painful, ulcerated, prior infection, or pedunculated), or when there is documented evidence of physical functional impairment
- B. **Select Health covers pulsed dye laser treatment of warts, hemangiomas, or pyogenic granulomas**, if they are symptomatic or causing a functional impairment, or if the member has failed 6 to 12 months of standard therapy.
- Examples of standard therapy, include:
- 1) For warts, attempts at cryotherapy, salicylic acid, and toxic agents have failed.
 - 2) For hemangiomas, topical beta blocker therapy has failed.
 - 3) For pyogenic granulomas, surgical removal, if possible.
- C. **Select Health does NOT cover pulsed dye laser treatment of port-wine birthmarks for cosmetic or psychological reasons.** Use for cosmetic or psychological reasons falls under the plan's cosmetic exclusion of coverage.
- D. **Select Health will cover pulsed dye laser treatment for symptomatic rosacea (e.g., skin sensitivity or papules/pustules)** if the patient has failed extensive conservative therapy* for this condition.

*Trial of at least 3 different medications (topical or oral) in a 12-month period, with documentation showing that symptoms persisted despite consistent use with each medication.

SELECT HEALTH ADVANTAGE (MEDICARE/CMS)

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the Select Health Commercial policy applies. For the most up-to-date Medicare policies and coverage, please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp&> or [the manual website](#)

SELECT HEALTH COMMUNITY CARE (MEDICAID)

Coverage is determined by the State of Utah Medicaid program; if Utah State Medicaid has no published coverage position and InterQual criteria are not available, the Select Health Commercial criteria will apply. For the most up-to-date Medicaid policies and coverage, please visit their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Summary of Medical Information

The pulsed dye laser delivers energy at a wavelength and duration that has been optimized for the selective treatment of vascular lesions. It has been used in the treatment of warts, port-wine birthmarks, hemangiomas, hypertrophic scars, and telangiectasias. Pulsed dye lasers have been used as an alternative to surgical excision or carbon dioxide lasers for many conditions.

The Food and Drug Administration (FDA) has cleared the pulsed-dye laser for use in treatment of warts, port-wine birthmarks, hemangiomas, hypertrophic scars, and telangiectasias. The pulsed-dye laser has

Pulsed Dye Laser Treatment of Congenital Hemangiomas and Rosacea, continued

been shown to be effective in treating glomangiomas in the face and neck, as surgical excision may not be practical in these cosmetically sensitive areas. The pulsed dye laser has also shown to be effective in removing pyogenic granulomas in cosmetically sensitive areas of the face and neck.

Billing/Coding Information

Covered: For the conditions outlined above

CPT CODES

- 17106** Destruction of cutaneous vascular proliferative lesions (e.g., laser technique); less than 10 sq cm
- 17107** ; 10.0 to 50.0 sq cm
- 17108** ; over 50.0 sq cm
- 96999** Unlisted special dermatological service or procedure

HCPCS CODES

No specific codes identified

Key References

1. Anolik R, Newlove T, Weiss ET, et al. Investigation into optimal treatment intervals of facial port-wine stains using the pulsed dye laser. *J Am Acad Dermatol* 2012; 67:985.
2. Apikian M, Goodman GJ, Roberts S. Management of mild to moderate rhinophyma with a 1,450-nm diode laser: report of five patients. *Dermatol Surg* 2007; 33:847.
3. Berg M, Edström DW. Flashlamp pulsed dye laser (FPDL) did not cure papulopustular rosacea. *Lasers Surg Med* 2004; 34:266.
4. Chang HC, Chang YS. Pulsed dye laser versus intense pulsed light for facial erythema of rosacea: a systematic review and meta-analysis. *J Dermatolog Treat*. 2022 Jun;33(4):2394-2396.
5. Chapas AM, Eickhorst K, Geronemus RG. Efficacy of early treatment of facial port wine stains in newborns: a review of 49 cases. *Lasers Surg Med* 2007; 39:563.
6. Chen JK, Ghasri P, Aguilar G, et al. An overview of clinical and experimental treatment modalities for port wine stains. *J Am Acad Dermatol* 2012; 67:289.
7. Chinnadurai S, Sathe NA, Surawicz T. Laser treatment of infantile hemangioma: A systematic review. *Lasers Surg Med*. 2016 Mar;48(3):221-33.
8. Comparative Effectiveness Review of Laser and Light Therapies for Rosacea. (2018, 25 January, updated 2022). *Hayes, Inc.* reviewed 24Oct22
9. Faurschou, A., Oleson, A., Leonardi-Bee, J., & Haedersdal, M. (2011). Treatment of port-wine stains with lasers or light sources. *Cochrane*. Retrieved from https://www.cochrane.org/CD007152/SKIN_treatment-of-port-wine-stains-with-lasers-or-light-sources, October 24, 2022.
10. Faurschou A, Togsverd-Bo K, Zachariae C, Haedersdal M. Pulsed dye laser vs. intense pulsed light for port-wine stains: a randomized side-by-side trial with blinded response evaluation. *Br J Dermatol* 2009; 160:359.
11. Frohm Nilsson M, Passian S, Wiegble Edstrom D. Comparison of two dye lasers in the treatment of port-wine stains. *Clin Exp Dermatol* 2010; 35:126.
12. Gao K, Huang Z, Yuan KH, et al. Side-by-side comparison of photodynamic therapy and pulsed-dye laser treatment of port-wine stain birthmarks. *Br J Dermatol* 2013; 168:1040.
13. Goldberg DJ. Lasers and light sources for rosacea. *Cutis* 2005; 75:22.
14. Groot D, Rao J, Johnston P, Nakatsui T. Algorithm for using a long-pulsed Nd:YAG laser in the treatment of deep cutaneous vascular lesions. *Dermatol Surg* 2003; 29:35.
15. Ibrahim SMA, Soliman M, Mohamed SKA, Soliman MM. Pulsed dye laser versus Nd:YAG laser in the treatment of recalcitrant plantar warts: an intraindividual comparative study. *J Cosmet Laser Ther*. 2021 Aug;23(5-6):130-136.
16. Izikson L, Anderson RR. Treatment endpoints for resistant port wine stains with a 755 nm laser. *J Cosmet Laser Ther* 2009; 11:52.
17. Jasim ZF, Handley JM. Treatment of pulsed dye laser-resistant port wine stain birthmarks. *J Am Acad Dermatol* 2007; 57:677.
18. Kassir R, Kolluru A, Kassir M. Intense pulsed light for the treatment of rosacea and telangiectasias. *J Cosmet Laser Ther* 2011; 13:216.
19. Katz B, Patel V. Photodynamic therapy for the treatment of erythema, papules, pustules, and severe flushing consistent with rosacea. *J Drugs Dermatol* 2006; 5:6.
20. Laube S, Taibjee S, Lanigan SW. Treatment of resistant port wine stains with the V Beam pulsed dye laser. *Lasers Surg Med* 2003; 33:282.
21. Lowe NJ, Behr KL, Fitzpatrick R, et al. Flash lamp pumped dye laser for rosacea-associated telangiectasia and erythema. *J Dermatol Surg Oncol* 1991; 17:522.
22. Madan V, Ferguson JE, August PJ. Carbon dioxide laser treatment of rhinophyma: a review of 124 patients. *Br J Dermatol* 2009; 161:814.
23. Ortiz AE, Nelson JS. Port-wine stain laser treatments and novel approaches. *Facial Plast Surg* 2012; 28:611.
24. Savas JA, Ledon JA, Franca K, et al. Pulsed dye laser-resistant port-wine stains: mechanisms of resistance and implications for treatment. *Br J Dermatol* 2013; 168:941.

Pulsed Dye Laser Treatment of Congenital Hemangiomas and Rosacea, continued

25. Stier MF, Glick SA, Hirsch RJ. Laser treatment of pediatric vascular lesions: Port wine stains and hemangiomas. J Am Acad Dermatol 2008; 58:261.
26. Taub AF, Devita EC. Successful treatment of erythematotelangiectatic rosacea with pulsed light and radiofrequency. J Clin Aesthet Dermatol 2008; 1:37.
27. Tierney EP, Hanke CW. Alexandrite laser for the treatment of port wine stains refractory to pulsed dye laser. Dermatol Surg 2011; 37:1268.
28. Togsverd-Bo K, Wiegell SR, Wulf HC, Haedersdal M. Short and limited effect of long-pulsed dye laser alone and in combination with photodynamic therapy for inflammatory rosacea. J Eur Acad Dermatol Venereol 2009; 23:200.
29. Veitch D, Kravvas G, Al-Niaimi F. Pulsed Dye Laser Therapy in the Treatment of Warts: A Review of the Literature. Dermatol Surg. 2017 Apr;43(4):485-493.
30. Yuan KH, Li Q, Yu WL, Huang Z. Photodynamic therapy in treatment of port wine stain birthmarks—recent progress. Photodiagnosis Photodyn Ther 2009; 6:189.

Revision History

Revision Date	Summary of Changes
11/20/23	For Commercial Plan Policy, modified requirements concerning failure of standard therapies.
10/17/24	Modified title of policy (was previously titled, “Pulsed Dye Laser Treatment of Congenital Hemangiomas and Rosacea”); and for Commercial Plan Policy, updated terminology from port-wine stains (PWS) to port-wine birthmarks (PWB) to align with current clinical standards.

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate healthcare providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Select Health® makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. Select Health updates its Coverage Policies regularly, and reserves the right to amend these policies without notice to healthcare providers or Select Health members.

Members may contact Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Coverage Policy may call Select Health Provider Relations at (801) 442-3692.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Select Health.

“Intermountain Healthcare” and its accompanying logo, the marks of “Select Health” and its accompanying marks are protected and registered trademarks of the provider of this Service and/or Intermountain Health Care, Inc., IHC Health Services, Inc., and Select Health, Inc. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association



MEDICAL POLICY

MONOCHROMATIC PHOTOTHERAPY (ANODYNE THERAPY)

Policy # 151

Implementation Date: 8/15/03

Review Dates: 6/24/04, 5/20/05, 5/3/06, 5/17/07, 4/24/08, 4/23/09, 4/22/10, 9/15/11, 11/29/12, 10/24/13, 10/23/14, 10/15/15, 10/20/16, 10/19/17, 10/3/18, 10/15/19, 10/14/20, 11/28/21, 9/15/22, 10/17/23, 10/29/24

Revision Dates:

Disclaimer:

1. Policies are subject to change without notice.
2. Policies outline coverage determinations for Select Health Commercial, Select Health Advantage (Medicare/CMS), and Select Health Community Care (Medicaid/CHIP) plans. Refer to the "Policy" section for more information.

Description

The Anodyne Therapy System (developed by Integrated Systems Physiology Inc.) delivers low-level infrared (890 nm) therapy directly to the skin of the affected tissue by an array of 60 super-luminous gallium aluminum arsenide diodes located on a flexible pad, 3 cm by 7.5 cm (22.5 cm²). The average energy emitted from the diodes is 9 milliwatts per square centimeter. The density of the photo energy emitted per pad during a 30-minute treatment is 43.2 Joules/cm.

COMMERCIAL PLAN POLICY AND CHIP (CHILDREN'S HEALTH INSURANCE PROGRAM)

Select Health does NOT cover monochromatic photo/light therapy for any indication. The quality peer-reviewed medical literature has failed to demonstrate this therapy to be effective for any clinical indication; this meets the plan's definition of experimental/investigational.

SELECT HEALTH MEDICARE

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the Select Health Commercial policy applies. For the most up-to-date Medicare policies and coverage, please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp&> or the manual website

SELECT HEALTH COMMUNITY CARE (MEDICAID)

Coverage is determined by the State of Utah Medicaid program; if Utah State Medicaid has no published coverage position and InterQual criteria are not available, the Select Health Commercial criteria will apply. For the most up-to-date Medicaid policies and coverage, please visit their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Summary of Medical Information

Diabetes mellitus affects over 16 million people in the United States, and nearly 30% of all diabetics develop neuropathy, a disorder that often causes progressive debilitation. Diabetic neuropathy is thought to arise from glycation of neural tissue during episodes of hyperglycemia and results in pain, loss of sensation, and muscle weakness. Loss of sensation can predispose patients to ulcerations of the feet since they cannot feel damaging pressure on or abrading of their skin. Neuropathy appears to further

Monochromatic Phototherapy (Anodyne Therapy), continued

contribute to ulceration by inhibiting normal vasodilation and increasing focal hypoxia in the ankle, foot, or toes. Another damaging process is that, in diabetic patients, local tissue stresses tend to result in thrombosis and necrosis rather than the more benign inflammatory response that occurs in nondiabetic patients. Since hyperglycemia plays a role in the development of neuropathy, diabetics with neuropathy are urged to maintain glycemic control as fully as possible with diet and insulin injection. Neuropathic pain may respond to anesthetics, antidepressants, analgesics, and certain other medications, whereas muscle weakness may be improved by physical therapy and exercise. In many cases, ulcerations of the lower extremities can also be prevented if patients follow a rigorous foot and skin care program.

Although the standard therapies for diabetic neuropathy are effective for some patients, many diabetics receive little benefit from treatment. According to one estimate, treatments for neuropathy, foot ulcers, and amputation for failed ulcer treatment account for half of all diabetic care costs in the United States. Monochromatic phototherapy or monochromatic near-infrared photo energy (MIRE) treatment has been studied as a way to reverse neuropathic damage by irradiation of affected areas with monochromatic infrared light. Proponents of this therapy suggest that monochromatic photo-therapy with 890 nm light may stimulate nitric oxide release, cause local vasodilation, improve circulation, and heal damaged nerves. Monochromatic phototherapy is administered in an office or clinic setting by a variety of healthcare professionals, including orthopedists, podiatrists, physiatrists, physical therapists, and chiropractors.

In April 2008, Hayes Directory re-reviewed this technology. Results of the uncontrolled and observational trials suggested that low level light therapy (LLLT) may lower the incidence and speed healing of diabetic ulcers and reduce the incidence of falls. However, 3 randomized, placebo-controlled trials failed to provide evidence that LLLT has a positive effect on overall neuropathy-specific disability. Although there is some evidence from observational and uncontrolled studies that LLLT may improve sensation in patients with peripheral neuropathy, randomized, placebo-controlled trials failed to confirm these findings. There was limited evidence from one randomized, placebo-controlled trial that LLLT in laser form may provide modest but transient pain relief, however, another placebo-controlled trial of the ATS did not report an effect on pain. There was very weak evidence that LLLT reduces the incidence of diabetic ulcers and limited evidence of a short-term reduction in falls, but these effects were not tested in randomized trials. Therefore, a Hayes Rating of 'D' is assigned to the use of LLLT for peripheral neuropathy. This rating is based on contradictory or negative evidence for most outcomes and only very weak evidence of an impact on incidence of falls and foot ulcers.

Billing/Coding Information

CPT CODES

- | | |
|--------------|---|
| 0552T | Low-level laser therapy, dynamic photonic and dynamic thermokinetic energies, provided by a physician or other qualified health care professional |
| 97026 | Application of a modality to one or more areas; infrared |
| 97037 | Application of a modality to 1 or more areas; low-level laser therapy (ie, nonthermal and non-ablative) for post-operative pain reduction |
| 97039 | Unlisted modality (specify type and time if constant attendance) |

HCPCS CODES

- | | |
|--------------|-----------------------------|
| E0221 | Infrared heating pad system |
|--------------|-----------------------------|

Key References

1. Beckerman H, de Ble R, Bouter L, et al. The efficacy of laser therapy for musculoskeletal and skin disorders: a criteria-based meta-analysis of randomized clinical trials. *Physical Ther.* 1992; 72:483-491.
2. Cullum N, Nelson EA, Flemming K, et al. Systematic reviews of wound care management: (5) beds; (6) compression; (7) laser therapy, therapeutic ultrasound, electrotherapy and electromagnetic therapy. *Health Technology Assessment.* Vol. 5, No. 9.
3. Flemming K, Cullum N. Laser therapy for venous leg ulcers. *Cochrane Review.* In: *The Cochrane Library*, Issue 4/01. Oxford, UK: Update Software; 2001.

Monochromatic Phototherapy (Anodyne Therapy), continued

4. Flemming KA, Cullum NA, Nelson EA. A systematic review of laser therapy for venous leg ulcers. *J Wound Care*. 1999;8(3):111-114.
5. Glasgow PD, Hill ID, McKevitt AM, et al. Low intensity monochromatic infrared therapy: a preliminary study of the effects of a novel treatment unit upon experimental muscle soreness. *Lasers Surg Med*. 2001;28(1):33-39.
6. Gogia PP, Hurt BS, Zim TT. Wound management with whirlpool and infrared cold laser treatment. A clinical report. *Phys Ther* 1988;68(8):1239-1242.
7. Gupta AK, Filonenko N, Salansky N, Sauder DN. The use of low energy photon therapy (LEPT) in venous leg ulcers: a double-blind, placebo-controlled study. *Dermatol Surg*. 1998;24(12):1383-1386.
8. Hayes Alert newsletter, April 2008.
9. Horwitz LR, Burke TJ, Carnegie D. Augmentation of wound healing using monochromatic infrared energy. Exploration of a new technology for wound management. *Adv Wound Care*. 1999;12(1):35-40.
10. Kochman AB, Carnegie DH, Burke TJ. *J Am Podiatr Med Assoc* 2002 Mar;92(3):125-30. Symptomatic reversal of peripheral neuropathy in patients with diabetes. PMID: 11904323
11. Lagan KM, Clements BA, McDonough S, Baxter GD. Low intensity laser therapy (830nm) in the management of minor post-surgical wounds: a controlled clinical study. *Lasers Surg Med*. 2001;28(1):27-32.
12. Miriutova NF, Abdulkina NG, Luksha LV, Levitskii EF. [Laser therapy and electric stimulation in rehabilitation treatment of peripheral neuropathy]. *Vopr Kurortol Fizioter Lech Fiz Kult*. 2002 Jul-Aug;(4):25-7. Russian. PMID: 12380528
13. Schneider WL, Hailey D. Low level laser therapy for wound healing. Alberta Heritage Foundation for Medical Research. Alberta, Canada: AHFMR; 1999.
14. The National Coordinating Centre for Health Technology Assessment (NCCHTA). 13665278. Southampton, UK: NCCHTA; 2001.

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate healthcare providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Select Health® makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. Select Health updates its Coverage Policies regularly, and reserves the right to amend these policies without notice to healthcare providers or Select Health members.

Members may contact Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Coverage Policy may call Select Health Provider Relations at (801) 442-3692.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Select Health.

"Intermountain Healthcare" and its accompanying logo, the marks of "Select Health" and its accompanying marks are protected and registered trademarks of the provider of this Service and or Intermountain Health Care, Inc., IHC Health Services, Inc., and Select Health, Inc. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association



MEDICAL POLICY

PHOTODYNAMIC THERAPY FOR ACTINIC KERATOSES

Policy # 311

Implementation Date: 9/30/05

Review Dates: 6/22/06, 8/23/07, 8/21/08, 8/13/09, 9/15/11, 11/29/12, 12/19/13, 12/18/14, 3/19/15, 2/11/16, 2/16/17, 2/15/18, 2/2/19, 2/17/20, 2/18/21, 1/10/22, 2/16/23, 2/23/24, 2/6/25

Revision Dates: 9/30/06

Disclaimer:

1. Policies are subject to change without notice.
2. Policies outline coverage determinations for Select Health Commercial, Select Health Medicare (CMS), and Select Health Community Care (Medicaid) plans. Refer to the "Policy" section for more information.

Description

Actinic Keratoses and Photodynamic Therapy: Clinical Overview

Actinic keratoses (AKs) are common precancerous skin lesions that arise due to cumulative sun exposure over time. These lesions typically present as single or multiple rough, scaly, or crusted plaques on sun-exposed areas of the skin, often emerging in early adulthood and increasing in prevalence with age. AKs range in color from pink to red, brown, or light gray, and they are often poorly margined upon palpation. As the most prevalent premalignant skin lesions, AKs develop in approximately 60% of individuals over 40 years of age who are predisposed due to chronic ultraviolet (UV) exposure.

While most AKs can be effectively treated, they pose a risk of malignant transformation into invasive squamous cell carcinoma (SCC). The likelihood of progression in immunocompetent patients is approximately 8%, though reported rates vary between 0.025% and 16%, depending on individual risk factors. Immunocompromised patients face a significantly elevated risk of AKs evolving into SCC, necessitating more aggressive surveillance and management.

Photodynamic Therapy for Actinic Keratoses

Photodynamic therapy (PDT) is an established, non-invasive treatment for AKs that utilizes a light-activated photosensitizer to selectively target and destroy precancerous cells. The treatment process consists of two key steps:

1. **Photosensitizer Application**
A topical photosensitizing agent—either 5-aminolevulinic acid (5-ALA) or methyl aminolevulinate (MAL)—is applied directly to the lesion using a specialized applicator. These agents penetrate the hyperkeratotic epidermis and are selectively metabolized within abnormal keratinocytes, leading to the intracellular accumulation of protoporphyrin IX (Pp-IX), a highly photosensitive compound.
2. **Light Activation**
Following a prescribed incubation period (typically 3 to 48 hours, depending on lesion characteristics and clinical protocol), the treated area is exposed to a controlled light source. Light therapy can be delivered through noncoherent sources (e.g., blue or red light-emitting devices) or laser-based systems, with treatment duration generally lasting about 15 minutes. In the presence of oxygen, light activation of Pp-IX generates reactive oxygen species, such as singlet oxygen

Photodynamic Therapy for Actinic Keratoses, continued

and free radicals, which induce localized cytotoxic damage, leading to targeted destruction of AK cells.

Since 5-ALA and MAL do not selectively absorb into AK lesions alone, inadvertent application to adjacent photodamaged skin may result in unintended photosensitization of healthy tissue. Therefore, careful application is essential to minimize off-target effects.

Post-Treatment Considerations

Following PDT, treated AK lesions undergo an inflammatory response, typically manifesting as erythema, edema, burning sensation, and crusting, which resolve within 10 to 14 days. The healing process generally results in favorable cosmetic outcomes, making PDT a preferred choice for extensive field treatment in cosmetically sensitive areas such as the face and scalp. Depending on lesion response, additional treatment sessions may be required to achieve complete clearance.

By selectively targeting dysplastic cells while sparing surrounding tissue, PDT serves as an effective and well-tolerated option for the management of AKs, particularly for patients with multiple lesions or significant field cancerization.

COMMERCIAL PLAN POLICY AND CHIP (CHILDREN'S HEALTH INSURANCE PROGRAM)

Select Health covers photodynamic therapy using either blue or red light sources for the treatment of actinic keratoses, as current evidence suggests equal or possibly slightly superior efficacy and near equivalency in cost-effectiveness to other standard treatment methods.

SELECT HEALTH ADVANTAGE (MEDICARE/CMS)

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the Select Health Commercial policy applies. For the most up-to-date Medicare policies and coverage, please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp&> or [the manual website](#)

SELECT HEALTH COMMUNITY CARE (MEDICAID)

Coverage is determined by the State of Utah Medicaid program; if Utah State Medicaid has no published coverage position and InterQual criteria are not available, the Select Health Commercial criteria will apply. For the most up-to-date Medicaid policies and coverage, please visit their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Summary of Medical Information

Photodynamic Therapy for Actinic Keratoses: Evidence Review and Clinical Efficacy

A total of 18 studies were identified and analyzed in this review, including 12 well-designed randomized controlled trials (RCTs) comparing photodynamic therapy (PDT) using 5-aminolevulinic acid (5-ALA) or methyl aminolevulinate (MAL) to various treatment modalities:

- Placebo-Controlled Studies (5 studies)
- Comparative Studies Against Standard Therapies (3 studies)
- No-Treatment Controls (1 study)
- Alternative PDT Regimens (3 studies)

Photodynamic Therapy for Actinic Keratoses, continued

Collectively, these studies consistently conclude that PDT with either 5-ALA or MAL is an effective treatment for AKs, demonstrating superior cosmetic outcomes compared to other standard therapies.

Efficacy of PDT in Randomized Controlled Trials

In a double-blind, placebo-controlled study by Dragieva et al., 17 patients (120 AKs) underwent treatment with two consecutive MAL applications. Two AKs per patient were randomly selected for treatment, while others received placebo cream. After 16 weeks, the treated areas showed complete clearance in 13 patients (76%) and partial clearance in 3 patients (18%), whereas none of the placebo-treated lesions improved.

Similarly, in a randomized, double-blind study by Pariser et al., 80 patients were assigned to either MAL-PDT with red light therapy or placebo. After 3 months, 89% of PDT-treated lesions resolved completely compared to 38% in the placebo group (Pariser et al., 2003).

A more recent study by Gold et al. involved 16 patients who received a single dose of ALA with pulsed light therapy on one side of the face, while the opposite side received pulsed light alone. After 3 months, 78% of AK lesions treated with ALA-PDT had fully resolved, compared to 53.6% of untreated lesions (Gold et al., 2020).

Comparative Studies Against Standard Treatments

Fewer studies have directly compared PDT with other standard AK therapies, but available data suggest similar or superior efficacy:

- Szeimies et al. (2004) randomized 193 patients (699 AKs) to either cryotherapy with liquid nitrogen spray or MAL-PDT with red light therapy. After 3 months, lesion clearance rates were comparable (69% for PDT vs. 75% for cryotherapy).
- Freeman et al. (2003) studied 204 patients, assigning them to cryotherapy (1 session), MAL-PDT (2 sessions), or placebo PDT. After 3 months, 91% of AKs treated with PDT resolved, compared with 68% treated with cryotherapy and only 30% with placebo PDT.
- Smith et al. (2019) compared ALA-PDT (with either blue light or laser light) to topical 5-fluorouracil (5-FU). Blue light PDT was as effective as 5-FU and superior to laser light therapy, with better patient tolerability than 5-FU.

Long-Term Efficacy of PDT for AKs

Two studies assessed the durability of PDT response over a 12-month period:

- Wulf et al. (2006) conducted a study in 27 patients, randomly assigning them to red light therapy with MAL on one skin area, while another area remained untreated. After 12 months, 62% of treated lesions remained AK-free, compared to 35% of untreated lesions. Additionally, the mean time to new AK development was significantly longer in treated areas (9.6 months vs. 6.8 months in untreated areas).
- Gilbert et al. (2022) conducted a prospective trial where 15 patients received topical 5-FU for 5 days, followed by ALA-PDT on day six. After 12 months, 90% of treated AKs remained resolved, though the additive effect of 5-FU and PDT complicates interpretation of these results.

Cost-Effectiveness and Considerations

A December 2004 M-Tech review acknowledged that PDT achieves similar efficacy to blue light therapy and other standard AK treatments. However, concerns regarding long-term cost-effectiveness persist due to higher treatment costs and a lack of direct comparative studies on economic benefits. No robust cost-effectiveness analyses for PDT have been published since this report.

Photodynamic Therapy for Actinic Keratoses, continued

Recent studies highlight additional unresolved issues:

1. **Adherence and Cosmetic Benefits**
PDT is often promoted as a more convenient and cosmetically favorable option compared to cryotherapy, 5-FU, or surgical excision. However, despite high patient satisfaction rates, no current literature provides direct evidence that PDT leads to higher adherence rates compared to other therapies (Braathen et al., 2021).
2. **High Spontaneous Clearance Rates**
Several studies report that untreated AKs can spontaneously resolve in 35–53.6% of cases (Dragieva et al., 2004; Pariser et al., 2003; Wulf et al., 2006). This raises concerns about potential overtreatment and whether all AKs require intervention to prevent SCC progression. Further research is necessary to identify which AKs are most likely to progress to SCC and which may regress without intervention.

Conclusion

Current evidence supports PDT as an effective treatment for AKs, offering comparable or superior efficacy to standard therapies with better cosmetic outcomes and patient satisfaction. However, cost-effectiveness, optimal treatment regimens, and adherence benefits remain areas requiring further research. Additionally, more studies are needed to differentiate AKs that require treatment from those that will regress spontaneously, thereby refining clinical decision-making and ensuring judicious use of PDT.

Billing/Coding Information

Covered: For the conditions outlined above

CPT CODES

96567 Photodynamic therapy by external application of light to destroy premalignant and/or malignant lesions of the skin and adjacent mucosa (e.g., lip) by activation of photosensitive drug(s), each phototherapy exposure session

HCPCS CODES

J7308 Aminolevulinic acid HCl for topical administration 20%, single unit dosage form (354 mg)

Key References

1. AHRQ [Oregon Health & Science University Evidence-based Practice Center] Evidence Report: Actinic Keratoses. May 19, 2001
2. American Academy of Dermatology (AAD) Position Statement on Actinic Keratosis. (Approved by the Board of Directors March 1999);
3. American Academy of Dermatology. Guidelines of care for actinic keratoses. Committee on Guidelines of Care. 1995
4. Avram DK, Goldman MP. Effectiveness and safety of ALA-IPL in treating actinic keratoses and photodamage. *J Drugs Dermatol*. 2004 Jan-Feb;3(1 Suppl): S36-9. PMID: 14964760
5. Berman B, Bienstock L, Kuritzky L, Mayeaux EJ, Jr., Tying SK. "Actinic keratoses: sequelae and treatments. Recommendations from a consensus panel." *J Fam Pract* 55.5 (2006): suppl 1-8.
6. Bissonette R, Bergeron A, Liu Y. Large surface photodynamic therapy with aminolevulinic acid: treatment of actinic keratoses and beyond. *J Drugs Dermatol*. 2004 Jan-Feb; 3(1 Suppl): S26-31. Review. PMID: 14964758
7. Braathen LR, Morton CA, Szeimies RM, et al. (2021). Patient adherence and satisfaction with photodynamic therapy for actinic keratoses. *Br J Dermatol*, 185(2), 432-439.
8. Carreon LY, Glassman SD, Anekstein Y, Puno RM. "Platelet gel (AGF) fails to increase fusion rates in instrumented posterolateral fusions." *Spine* 30.9 (2005): E243-6; discussion E247.
9. Cerburkovas O, Krause M, Ulrich J, Bonnekoh B, Gollnick H. [Disseminated actinic keratoses. Comparison of topical photodynamic therapy with 5-aminolevulinic acid and topical 5% imiquimod cream]. *Hautarzt*. 2001 Oct;52(10 Pt 2):942-6. German. PMID: 11715389
10. Chamberlain AJ, Kurwa HA. Photodynamic therapy: is it a valuable treatment option for actinic keratoses? *Am J Clin Dermatol*. 2003;4(3):149-55. Review. PMID: 12627990
11. Clark C, Bryden A, Dawe R, Moseley H, Ferguson J, Ibbotson SH. Topical 5-aminolevulinic acid photodynamic therapy for cutaneous lesions: outcome and comparison of light sources. *Photodermatol Photoimmunol Photomed*. 2003 Jun;19(3):134-41. PMID: 12914598
12. Collaud S, Juzeniene A, Moan J, Lange N. On the selectivity of 5-aminolevulinic acid-induced protoporphyrin IX formation. *Curr Med Chem Anti-Canc Agents*. 2004 May;4(3):301-16. Review. PMID: 15134506
13. Dijkstra AT, Majoe IM, van Dongen JW, van Weelden H, van Vloten WA. Photodynamic therapy with violet light and topical 6-aminolevulinic acid in the treatment of actinic keratosis, Bowen's disease and basal cell carcinoma. *J Eur Acad Dermatol Venereol*. 2001 Nov;15(6):550-4. PMID: 11843215

Photodynamic Therapy for Actinic Keratoses, continued

14. Dragieva G, Prinz BM, Hafner J, Dummer R, Burg G, Binswanger U, Kempf W. A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolevulinate in the treatment of actinic keratoses in transplant recipients. *Br J Dermatol*. 2004 Jul;151(1):196-200. PMID: 15270891
15. Drugs.com. Fluoroplex Topical Cream. 2006. Available: http://www.drugs.com/pdr/fluoroplex_topical_cream.html. Date Accessed: July 16, 2006.
16. Epstein E. Quantifying actinic keratosis: assessing the evidence. *Am J Clin Dermatol*. 2004;5(3):141-4. Review. PMID: 15186192
17. Expert Group on Renal Transplantation (EBPG). European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.2. Cancer risk after renal transplantation. Skin cancers: prevention and treatment. 2002.
18. Foley P. Clinical efficacy of methyl aminolevulinate (Metvix) photodynamic therapy. *J Dermatolog Treat*. 2003;14 Suppl 3:15-22. Review. PMID: 14522637
19. Food and Drug Administration. "Methyl aminolevulinate." (2004).
20. Food and Drug Administration. Levulan® Kerastick®, 1999.
21. Fowler JF Jr, Zax RH. Aminolevulinic acid hydrochloride with photodynamic therapy: efficacy outcomes and recurrence 4 years after treatment. *Cutis*. 2002 Jun;69(6 Suppl):2-7. PMID: 12095067
22. Freeman M, Vincicullo C, Francis D, Spelman L, Nguyen R, Fergin P, Thai KE, Murrell D, Weightman W, Anderson C, Reid C, Watson A, Foley P. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. *J Dermatolog Treat*. 2003 Jun;14(2):99-106. PMID: 12775317
23. Gilbert DJ. "Treatment of actinic keratoses with sequential combination of 5-fluorouracil and photodynamic therapy." *J Drugs Dermatol* 4.2 (2005): 161-3.
24. Gilbert DJ, Magnusson M, Edwards SL, et al. (2022). Long-term clearance of actinic keratoses with 5-FU pre-treatment followed by ALA-PDT: A 12-month prospective study. *Lasers Surg Med*, 54(7), 987-995.
25. Glover JL, Weingarten MS, Buchbinder DS, Poucher RL, Deitrick GA, 3rd, Fyelling CP. "A 4-year outcome-based retrospective study of wound healing and limb salvage in patients with chronic wounds." *Adv Wound Care* 10.1 (1997): 33-8.
26. Gold MH, Bradshaw VL, Boring MM, Bridges TM, Biron JA. "Split-face comparison of photodynamic therapy with 5-aminolevulinic Acid and intense pulsed light versus intense pulsed light alone for photodamage." *Dermatol Surg* 32.6 (2006): 795-803.
27. Gold MH, Goldman MP. 5-aminolevulinic acid photodynamic therapy: where we have been and where we are going. *Dermatol Surg*. 2004 Aug;30(8):1077-83; discussion 1083-4. Review. PMID: 15274696
28. Gold MH, Sikes J, Birnie AJ, et al. (2020). Efficacy of 5-ALA photodynamic therapy for actinic keratoses: A randomized controlled trial. *J Am Acad Dermatol*, 82(4), 1045-1052.
29. Goldman M, Atkin D. ALA/PDT in the treatment of actinic keratosis: spot versus confluent therapy. *J Cosmet Laser Ther*. 2003 Jun;5(2):107-10. PMID: 12850802
30. Hayes Directory. Photodynamic Therapy for Actinic Keratoses. Lansdale, PA: Winifred S. Hayes, Inc., 2004.
31. Hee HT, Majd ME, Holt RT, Myers L. "Do autologous growth factors enhance transforaminal lumbar interbody fusion?" *Eur Spine J* 12.4 (2003): 400-7.
32. Jeffes EW, McCullough JL, Weinstein GD, Fergin PE, Nelson JS, Shull TF, Simpson KR, Bukaty LM, Hoffman WL, Fong NL. Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid. A pilot dose-ranging study. *Arch Dermatol*. 1997 Jun;133(6):727-32. PMID: 9197826
33. Jeffes EW, McCullough JL, Weinstein GD, Kaplan R, Glazer SD, Taylor JR. Photodynamic therapy of actinic keratoses with topical aminolevulinic acid hydrochloride and fluorescent blue light. *J Am Acad Dermatol*. 2001 Jul;45(1):96-104. PMID: 11423841
34. Kasche A, Luderschmidt S, Ring J, Hein R. "Photodynamic therapy induces less pain in patients treated with methyl aminolevulinate compared to aminolevulinic acid." *J Drugs Dermatol* 5.4 (2006): 353-6.
35. Kennedy JC, Marcus SL, Pottier RH. Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): mechanisms and clinical results. *J Clin Laser Med Surg*. 1996 Oct;14(5):289-304. Review. PMID: 9612195
36. Kurwa HA, Yong-Gee SA, Seed PT, Markey AC, Barlow RJ. A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses. *J Am Acad Dermatol*. 1999 Sep;41(3 Pt 1):414-8. PMID: 10459115
37. Lang K, Lehmann P, Bolsen K, Ruzicka T, Fritsch C. Aminolevulinic acid: pharmacological profile and clinical indication. *Expert Opin Investig Drugs*. 2001 Jun;10(6):1139-56. Review. PMID: 11772241
38. Lober BA, Fenske NA. "Optimum treatment strategies for actinic keratosis (intraepidermal squamous cell carcinoma)." *Am J Clin Dermatol* 5.6 (2004): 395-401.
39. Madigan Army Medical Center. Specialty: Dermatology. Actinic (Solar) Keratosis, Squamous Cell Carcinoma, and Basal Cell Carcinoma. Referral Guideline Published: 25 May 2004.
40. Marcus L. Photodynamic therapy for actinic keratosis followed by 5-fluorouracil reaction. *Dermatol Surg*. 2003 Oct;29(10):1061-4; discussion 1064-5. PMID: 12974706
41. Marmur ES, Schmults CD, Goldberg DJ. A review of laser and photodynamic therapy for the treatment of nonmelanoma skin cancer. *Dermatol Surg*. 2004 Feb;30(2 Pt 2):264-71. Review. PMID: 14871220
42. Morton CA, Brown SB, Collins S, Ibbotson S, Jenkinson H, Kurwa H, Langmack K, McKenna K, Moseley H, Pearse AD, Stringer M, Taylor DK, Wong G, Rhodes LE. Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology Group. *Br J Dermatol*. 2002 Apr;146(4):552-67. Review. PMID: 11966684
43. Morton CA. The emerging role of 5-ALA-PDT in dermatology: is PDT superior to standard treatments? *J Dermatolog Treat*. 2002;13 Suppl 1: S25-9. Review. PMID: 12060514
44. Nakaseko H, Kobayashi M, Akita Y, Tamada Y, Matsumoto Y. Histological changes and involvement of apoptosis after photodynamic therapy for actinic keratoses. *Br J Dermatol*. 2003 Jan;148(1):122-7. PMID: 12534605
45. National Institute for Clinical Excellence. Interventional procedures overview of photodynamic therapy for non-melanoma skin tumours (including premalignant and primary, non-metastatic skin lesions). Great Britain, 2005.
46. Nestor MS, Gold MH, Kauvar AN, et al. "The use of photodynamic therapy in dermatology: results of a consensus conference." *J Drugs Dermatol* 5.2 (2006): 140-54.

Photodynamic Therapy for Actinic Keratoses, continued

47. Pariser DM, Lowe NJ, Stewart DM, Jarratt MT, Lucky AW, Pariser RJ, Yamauchi PS. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. *J Am Acad Dermatol*. 2003 Feb;48(2):227-32. PMID: 12582393
48. Piacquadio DJ, Chen DM, Farber HF, Fowler JF Jr, Glazer SD, Goodman JJ, Hruza LL, Jeffes EW, Ling MR, Phillips TJ, Rallis TM, Scher RK, Taylor CR, Weinstein GD. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials. *Arch Dermatol*. 2004 Jan;140(1):41-6. PMID: 14732659
49. Ruiz-Rodriguez R, Sanz-Sanchez T, Cordoba S. Photodynamic photorejuvenation. *Dermatol Surg*. 2002 Aug; 28(8):742-4; discussion 744. PMID: 12174070
50. RxList Inc. Carac: indications and usage. 2006. Available: http://www.rxlist.com/cgi/generic3/carac_ids.htm. Date Accessed: July 17, 2006.
51. RxList Inc. Efudex: indications and usage. 2006. Available: http://www.rxlist.com/cgi/generic3/fluor_ids.htm. Date Accessed: July 17, 2006.
52. RxList Inc. Imiquimod: indications and usage. 2006. Available: http://www.rxlist.com/cgi/generic/imiquimod_ids.htm. Date Accessed: July 17, 2006.
53. Shaw JC. "Actinic keratosis." UpToDate http://www.utdol.com/utd/content/topic.do?topicKey=pri_derm/12376&type=A&selectedTitle=1~7 (2006).
54. Siddiqui MA, Perry CM, Scott LJ. Topical methyl aminolevulinate. *Am J Clin Dermatol*. 2004;5(2):127-37; discussion 138-40. Review. PMID: 15109276
55. Smith S, Piacquadio D, Morhenn V, Atkin D, Fitzpatrick R. "Short incubation PDT versus 5-FU in treating actinic keratoses." *J Drugs Dermatol* 2.6 (2003): 629-35.
56. Smith S, Piacquadio D, Morhenn V, Atkin D, Fitzpatrick R. Short incubation PDT versus 5-FU in treating actinic keratoses. *J Drugs Dermatol*. 2003 Dec;2(6):629-35. PMID: 14711141
57. Smith S, Lawrence N, Braun R, et al. (2019). Comparison of blue light PDT, laser PDT, and topical 5-FU for actinic keratoses: A randomized study. *Dermatol Surg*. 45(3), 355-362.
58. Stefanidou M, Tosca A, Themelis G, Vazgiouraki E, Balas C. In vivo fluorescence kinetics and photodynamic therapy efficacy of delta-aminolevulinic acid-induced porphyrins in basal cell carcinomas and actinic keratoses; implications for optimization of photodynamic therapy. *Eur J Dermatol*. 2000 Jul-Aug;10(5):351-6. PMID: 10882942
59. Szeimies RM, Karrer S, Radakovic-Fijan S, et al. "Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: A prospective, randomized study." *J Am Acad Dermatol* 47.2 (2002): 258-62.
60. Szeimies RM, Karrer S, Radakovic-Fijan S, Tanew A, Calzavara-Pinton PG, Zane C, Sidoroff A, Hempel M, Ulrich J, Proebstle T, Meffert H, Mulder M, Salomon D, Dittmar HC, Bauer JW, Kemland K, Braathen L. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: A prospective, randomized study. *J Am Acad Dermatol*. 2002 Aug;47(2):258-62. PMID: 12140473
61. Szeimies RM, Karrer S, Sauerwald A, Landthaler M. Photodynamic therapy with topical application of 5-aminolevulinic acid in the treatment of actinic keratoses: an initial clinical study. *Dermatology*. 1996;192(3):246-51. PMID: 8726640
62. Taub AF. Photodynamic therapy in dermatology: history and horizons. *J Drugs Dermatol*. 2004 Jan-Feb;3(1 Suppl):S8-25. Review. PMID: 14964757
63. Touma D, Yaar M, Whitehead S, Konnikov N, Gilchrist B. A trial of short incubation, broad-area photodynamic therapy for facial actinic keratoses and diffuse photodamage. *Arch Dermatol*. 2004 Jan;140(1):33-40. PMID: 14732657
64. UpToDate: Actinic Keratoses
65. Whited JD, Homer Rd, Hall RP, et al. The influence of history on interobserver agreement for diagnosing actinic heratoses and malignant skin lesions. *J Am Acad Dermatol* 1995; 33: 603-7.
66. Winnington P. "Is it time to join the evolution?" *Practical Derm* 3.4 (2006): 23-26.
67. Wolf P, Fink-Puches R, Reimann-Weber A, Kerl H. Development of malignant melanoma after repeated topical photodynamic therapy with 5-aminolevulinic acid at the exposed site. *Dermatology*. 1997;194(1):53-4. PMID: 9031792
68. Wolf P, Rieger E, Kerl H. Topical photodynamic therapy with endogenous porphyrins after application of 5-aminolevulinic acid. An alternative treatment modality for solar keratoses, superficial squamous cell carcinomas, and basal cell carcinomas? *J Am Acad Dermatol*. 1993 Jan;28(1):17-21. Erratum in: *J Am Acad Dermatol* 1993 Jul;29(1):41. PMID: 8318069
69. Wulf HC, Pavel S, Stender I, Bakker-Wensveen CA. "Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients." *Acta Derm Venereol* 86.1 (2006): 25-8.

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate healthcare providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Select Health® makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. Select Health updates its Coverage Policies regularly, and reserves the right to amend these policies without notice to healthcare providers or Select Health members.

Members may contact Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Coverage Policy may call Select Health Provider Relations at (801) 442-3692.

Photodynamic Therapy for Actinic Keratoses, continued

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Select Health.

"Intermountain Healthcare" and its accompanying logo, the marks of "Select Health" and its accompanying marks are protected and registered trademarks of the provider of this Service and or Intermountain Health Care, Inc., IHC Health Services, Inc., and Select Health, Inc. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association



MEDICAL POLICY

PHOTOTHERAPIES FOR THE TREATMENT OF SKIN CONDITIONS

Policy # 351

Implementation Date: 5/14/07

Review Dates: 4/24/08, 4/23/09, 4/22/10, 5/21/11, 11/29/12, 12/19/13, 12/18/14, 12/10/15, 12/15/16, 12/21/17, 11/27/18, 12/18/19, 12/17/20, 12/14/21, 1/13/23, 12/22/23, 11/29/24

Revision Dates: 11/11/11, 10/24/16, 5/26/17, 1/14/19, 5/11/20, 5/3/21, 4/22/22, 12/12/22, 2/17/23, 4/16/24, 12/12/24, 5/8/25

Disclaimer:

1. Policies are subject to change without notice.
2. Policies outline coverage determinations for Select Health Commercial, Select Health Medicare (CMS), and Select Health Community Care (Medicaid) plans. Refer to the "Policy" section for more information.

Description

Approximately 1% of the population in North America is affected with psoriasis. Even when skin involvement is not severe, psoriasis affects the general health of patients with the disease in many ways not limited to lower quality of life, depression, anxiety, cardiovascular disease, sleep apnea, and arthritis, among others. Most patients with skin-limited and systemic psoriatic disease are treated in the outpatient setting. The severity of psoriasis is determined by the percentage of total affected body surface area (BSA). One percent of a body surface area roughly approximates the anterior hand including the fingers. Mild psoriasis involves < 3% BSA, moderate psoriasis involves 3%–10% BSA, and severe disease is considered, if more than 10% BSA is affected. Severe disease is also considered if the hands, feet, or scalp are involved.

Phototherapy is generally used on patients with moderate-to-severe psoriasis who have not responded to more conservative therapies. Phototherapies include but are not limited broadband UV-B, PUVA, narrowband UV-B, and laser therapies.

Broadband UV light can be either UV-A (BB-UVA) at a wavelength between 320–400 nanometers (nm) or UV-B (BB-UVB) at a wavelength between 290–320 nm; with the latter considered the standard broadband range. Multiple sessions (commonly 3x/week) over 3 or more months are often required to produce lesion-clearing. While supraerythemogenic doses of UVA and UVB result in faster clearing of the lesions, the surrounding normal skin cannot tolerate such high doses and predisposes patients to dermatoheliosis and risk of skin malignancies.

An alternative to office-based phototherapy is the use of a home ultraviolet B (UVB) phototherapy unit prescribed by the treating clinician. Like phototherapy in a clinic, it requires a consistent treatment schedule. Home phototherapy units that are equipped with electronic controls that allow only a prescribed number of treatments are available and may help to mitigate clinician concerns.

Narrowband UVB (311 nm) is an alternative to standard broadband (290–320 nm) UVB in the treatment of psoriasis. Suberythemogenic doses of narrowband UVB have been shown in small studies to be more effective than broadband UVB in clearing plaque psoriasis. Apoptosis of T cells is also more common with 311 nm than with broadband UVB. This is important in the treatment of many inflammatory skin conditions.

Photochemotherapy (PUVA) involves treatment with either oral or bath psoralen, followed by ultraviolet A (UVA) radiation (320–400 nm). This treatment is an alternative to UVB therapy and is frequently used when UVB fails. UVA penetrates deeper into the dermis than UVB and does not have the latter's potential for burning the skin. With oral PUVA, patients ingest the photosensitizing drug, 8-methoxypsoralen, followed within 2 hours by exposure to UVA; this sequence is performed 3 times weekly in increasing doses until remission, then twice or once weekly as a maintenance dose. With bath PUVA, the psoralen

Phototherapies for the Treatment of Skin Conditions continued

capsules are dissolved in water, and affected skin (hands, feet, or total body) is soaked for 15–30 minutes prior to UVA exposure.

Laser therapy works by producing intense beams of virtually non-divergent light. Xenon-chloride (XeCl) laser therapy, as delivered in a handheld device, has been used principally for patients with localized disease, involving less than 10% of the body. These patients are generally not considered candidates for other phototherapies, due to the risks of exposing the entire body to UV light. These patients are typically treated with topical therapies. Therefore, the safety and effectiveness of XeCl phototherapy must be compared to that of topical preparations. Relevant outcomes include percentage of lesions healed, time to healing, durability of healing, patient compliance with therapy (laser therapy requires multiple office visits), and the long-term effects of therapy. The side effect of greatest concern is the carcinogenic potential of UVB light exposure, although this risk may be minimized with a handheld device that spares normal skin.

COMMERCIAL PLAN POLICY AND CHIP (CHILDREN'S HEALTH INSURANCE PROGRAM)

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request.

A. Select Health covers office-based PUVA, narrowband UVB, broadband UVB, and excimer laser (308 nm)/excimer light (308 nm)/targeted NB-UVB light (311–313 nm) phototherapies for the treatment of psoriasis and mycosis fungoides.

B. Select Health covers office-based PUVA, narrowband UVB, and broadband UVB phototherapies for the treatment of atopic dermatitis, lichen planus, chronic idiopathic urticaria, morphea, polymorphous light eruption, and other related skin conditions, when the member has failed at least 3 months of aggressive standard therapy in the last 2 years, for any of the following therapies: topical therapy, oral immunosuppressants, or topical and/or oral steroids.

C. Select Health covers home phototherapy (narrowband UVB) for the treatment of psoriasis and other approved skin conditions in *limited* circumstances when the below criteria are met.

Criteria for coverage (Must meet ALL):

1. Patient has one of the following diagnoses:
 - a) Severe psoriasis (defined as psoriasis involving 10% BSA) refractory to topical therapy or nonbiologic systemic therapy, or
 - b) Cutaneous T-cell lymphoma (CTCL)/mycosis fungoides, or
 - c) Any of the skin conditions listed above with involvement of the palms or soles, also refractory to topical or nonbiologic medical therapy;

AND

2. Patient requires UVB light treatments at least 2 times per week; and
3. Treatment has been prescribed by a dermatologist; and
4.
 - a) Provider has documented member as having demonstrated measurable improvement with initial treatment in the provider's office after a minimum of 16 visits occurring within a 60-day period; or
 - b) If in-office therapy is not available, then rent-to-purchase UVB therapy will be available if the member has demonstrated measurable improvement after a minimum of 16 therapies within the 60-day period at home.

D. Contraindications to UVB Phototherapy:

Absolute Contraindications:

1. Xeroderma pigmentosum
2. Lupus erythematosus

Phototherapies for the Treatment of Skin Conditions, continued

Relative Contraindications:

1. History of photosensitivity diseases (e.g., chronic actinic dermatitis, solar urticaria)
2. History of melanoma
3. History of nonmelanoma skin cancer
4. History of treatment with arsenic or ionizing radiation because of the increased risk for skin cancer
5. Immunosuppression for organ transplant patients

Select Health does not cover any form of phototherapy for vitiligo; this is considered cosmetic.

SELECT HEALTH MEDICARE (CMS)

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the Select Health Commercial policy applies. For the most up-to-date Medicare policies and coverage, please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp&> or [the manual website](#)

SELECT HEALTH COMMUNITY CARE (MEDICAID)

Select Health Community Care policies typically align with State of Utah Medicaid policy, including use of InterQual. There may be situations where NCD/LCD criteria or Select Health commercial policies are used. For the most up-to-date Medicaid policies and coverage, please visit their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Summary of Medical Information

Published literature clearly suggests that PUVA and broadband UV-B and narrowband UV-B phototherapies are considered standard of care in the treatment of patients with moderate-to-severe psoriasis who do not respond to more conservative therapies. Studies have shown that the optimum wavelength of UVB for the treatment of psoriasis is close to 311 nm and this has led to the development of bulbs that emit UVB radiation in a 'narrowband' at this optimum wavelength. Some research has been limited to relatively short timeframes and confounded by the numerous measures of outcomes, varying indications (e.g., severity), and treatment protocols used, and general lack of control groups. As stated by Naldi et al.: "There is an urgent need to reset the research agenda focusing on long-term comparative RCTs." Additionally, these treatments are universally covered and supported by local and national dermatologists.

Hayes rated excimer laser therapy for plaque psoriasis in adult patients as a 'C' in 2022, and evidence suggests excimer laser is more effective than no treatment, and excimer laser plus certain topical medications may be more effective than medications alone. Evidence also suggests that excimer laser has similar efficacy as UVB phototherapy and PUVA. It seems clear that laser therapy is approximately as effective as UV-B phototherapy in clearing lesions and perhaps faster in doing so. What remains unknown is its safety: i.e., the risk of increasing squamous and basal cell carcinomas among these patients in the long-term, as well as its cost-effectiveness because it is an expensive device. While excimer laser therapy remains an option, especially for localized plaques, its cost and unclear long-term safety profile continue to limit its widespread use. Current literature still lacks robust comparative studies to establish it as a standard alternative to phototherapy or biologics.

A Medical Technology Assessment performed in June 2011 identified 2 systematic reviews and 6 primary literature articles concerning home UV treatment for psoriasis. Several of the studies involved direct comparison of home UVB therapy to outpatient UVB therapy. In the study by Koek et al. in 2009, the equivalent efficacy of this therapy was established. Other studies such as Nolan in 2010, and the Tayside study, identified that patients prefer home UV therapy. Nolan goes as far as to state: "Home phototherapy is a well-tolerated, efficacious, economical and patient friendly therapeutic option. Advantages of home phototherapy include improved quality of life, greater convenience, lower cost, and less time lost from

Phototherapies for the Treatment of Skin Conditions, continued

work and social activities. Dermatologists should strongly consider home phototherapy as a first-line treatment option for appropriately selected psoriasis patients." The LITE (Light Treatment Effectiveness) Study, concluded in 2023, is a landmark trial comparing the effectiveness and safety of home versus office-based narrowband UVB phototherapy for psoriasis. It found that home phototherapy is non-inferior to office treatments, with 60% of patients achieving clear or almost clear skin after consistent use (2+ sessions weekly for 12 weeks). This underscores narrowband UVB's role as an effective and equitable treatment across all skin types, with the added benefit of improving accessibility and adherence for patients, particularly those in rural or underserved areas.

Questions regarding adherence to home therapy were also addressed in several studies. This is exemplified in the study by Yentzer et al. In this study, adherence data on 22 patients using acitretin and 16 patients for adherence to UVB was collected. Mean adherence to acitretin decreased steadily during the 12-week trial, whereas mean adherence to home phototherapy remained steady at 2–3 days per week. Adherence was similar between patients who reported side effects and those who did not. Recent studies highlight the cost-effectiveness of home-based UVB therapy, especially for patients who face logistical or financial barriers to office-based treatments. The LITE study further reported that adherence to home phototherapy regimens is consistent and often higher compared to oral treatments, supporting its practical utility.

For most of the literature, the issues of concern are twofold: 1) compliance/adherence to the prescribed UV regimen, and 2) cost-effectiveness of home UV as it compares to either outpatient treatment at a clinic or treatment with biologic agents. This is exemplified by the comments from Nolan et al. (2010).

Overall, most papers were supportive of the use of UVB home phototherapy. The Australia and New Zealand Horizon Scanning Network summarized the findings by stating: "It would appear that home-based UVB therapy is as effective as that offered to outpatients in a hospital setting. In addition, there was no difference in the number of adverse events recorded between the two groups." The recent LITE study strongly supports the inclusion of both home and office-based narrowband UVB phototherapy in insurance coverage as a standard care option for psoriasis. This aligns with its established effectiveness, patient adherence, and equivalence to other systemic therapies in real-world settings. Expanding access to home phototherapy, in particular, addresses equity issues and reduces treatment burden for many patients.

Billing/Coding Information

Covered: For the conditions outlined above

CPT CODES

96900	Actinotherapy (ultraviolet light)
96910	Photochemotherapy; tar and ultraviolet B (Goeckerman treatment) or petrolatum and ultraviolet B
96912	Photochemotherapy; psoralens and ultraviolet A (PUVA)
96913	Photochemotherapy; (Goeckerman and/or PUVA) for severe photoresponsive dermatoses requiring at least four to eight hours of care under direct supervision of the physician (includes application of medication and dressings)
96999	Unlisted special dermatological service or procedure
96920	Laser treatment for inflammatory skin disease (psoriasis); total area less than 250 sq cm
96921	Laser treatment for inflammatory skin disease (psoriasis); 250 sq cm to 500 sq cm
96922	Laser treatment for inflammatory skin disease (psoriasis); over 500 sq cm

HCPCS CODES

Covered: For the conditions outlined above

A4633	Replacement bulb/lamp for ultraviolet light therapy system, each
--------------	--

Phototherapies for the Treatment of Skin Conditions, continued

- E0691** Ultraviolet light therapy system panel, includes bulbs/lamps, timer and eye protection; treatment area two square feet or less
- E0692** Ultraviolet light therapy system panel, includes bulbs/lamps, timer and eye protection, four foot panel
- E0693** Ultraviolet light therapy system panel, includes bulbs/lamps, timer and eye protection, six foot panel
- E0694** Ultraviolet multidirectional light therapy system in six foot cabinet, includes bulbs/lamps, timer and eye protection

Key References

1. Adelaide Health Technology Assessment (AHTA). (2010) Horizon Scanning Technology Prioritising Summary: Home ultraviolet B (UVB) phototherapy for the treatment of psoriasis. Australia and New Zealand Horizon Scanning Network (ANZHSN). March
2. Al-Robaee, AA, Al-Zolibani, AA, Al-Shobili, HA, et al. (2008). IL-10 implications in psoriasis. *Int J Health Sci (Qassim)* 2.1: 53-8.
3. Al-Suwaidan SN, Feldman SR. Clearance is not a realistic expectation of psoriasis treatment. *J Am Acad Dermatol*. 2000 May;42(5 Pt 1):796-802. PMID: 10775857
4. Anderson RR. Lasers in dermatology—a critical update. *J Dermatol*. 2000 Nov;27(11):700-5. Review. PMID: 11138535
5. Asawanonda P, Anderson RR, Chang Y, Taylor CR. 308-nm excimer laser for the treatment of psoriasis: a dose-response study. *Arch Dermatol*. 2000 May;136(5):619-24. PMID: 10815855
6. Bianchi B, Campolmi P, Mavilia L, Danesi A, Rossi R, Cappugi P. Monochromatic excimer light (308 nm): an immunohistochemical study of cutaneous T cells and apoptosis-related molecules in psoriasis. *J Eur Acad Dermatol Venereol*. 2003 Jul;17(4):408-13. PMID: 12834450
7. Bjerring P, Zachariae H, Sogaard H. The flashlamp-pumped dye laser and dermabrasion in psoriasis—further studies on the reversed Kobner phenomenon. *Acta Derm Venereol*. 1997 Jan;77(1):59-61. PMID: 9059681
8. Bope, ET. (2010). *Conn's Current Therapy*. 1 ed: Elsevier Saunders.
9. British Photodermatology Group Workshop Report; British Association of Dermatologists. An update and guidance on narrow-band ultraviolet B phototherapy: *Br J Dermatol*. 2004 Aug;151(2):283-97. PMID: 15327535
10. Cameron, H, Yule, S, Moseley, H, et al. (2002). Taking treatment to the patient: development of a home TL-01 ultraviolet B phototherapy service. *Br J Dermatol* 147.5: 957-65.
11. Dawe RS. A quantitative review of studies comparing the efficacy of narrow-band and broad-band ultraviolet B for psoriasis. *Br J Dermatol*. 2003 Sep;149(3):669-72. Review. PMID: 14511017
12. Eastmond, CJ. (1994). Psoriatic arthritis. Genetics and HLA antigens. *Baillieres Clin Rheumatol* 8.2: 263-76.
13. Elmets, C. A. Polymorphous light eruption. UpToDate. Last updated: Feb. 21, 2025.
14. Feldman SR, Garton R, Averett W, Balkrishnan R, Vallee J. Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost. *Expert Opin Pharmacother*. 2003 Sep;4(9):1525-33. Review. Erratum in: *Expert Opin Pharmacother*. 2003 Oct;4(10):1887. PMID: 12943482
15. Feldman SR, Mellen BG, Housman TS, Fitzpatrick RE, Geronemus RG, Friedman PM, Vasily DB, Morison WL. Efficacy of the 308-nm excimer laser for treatment of psoriasis: results of a multicenter study. *J Am Acad Dermatol*. 2002 Jun;46(6):900-6. PMID: 12063488
16. Feldman, S. R. (2011). Epidemiology, pathophysiology, clinical manifestations, and diagnosis of psoriasis. Last Update: December 16, 2010. UpToDate. Available: http://www.uptodate.com/contents/epidemiology-pathophysiology-clinical-manifestations-and-diagnosis-of-psoriasis?source=search_result&selectedTitle=2~150. Date Accessed: May 20, 2011.
17. Feldman, S.R. (2022). Treatment of psoriasis in adults. Last Update: Oct. 12, 2022. UpToDate. Available at: <https://www.uptodate.com/contents/treatment-of-psoriasis-in-adults>
18. Ferri, FF. (2011). *Ferri's Clinical Advisor* 2011. 1 ed: Elsevier Mosby.
19. Gerber W, Arheilger B, Ha TA, Hermann J, Ockenfels HM. Ultraviolet B 308-nm excimer laser treatment of psoriasis: a new phototherapeutic approach. *Br J Dermatol*. 2003 Dec;149(6):1250-8. PMID: 14674904
20. Gladman, DD, Anhorn, KA, Schachter, RK, et al. (1986). HLA antigens in psoriatic arthritis. *J Rheumatol* 13.3: 586-92.
21. Guidelines of care for psoriasis. Committee on Guidelines of Care. Task Force on Psoriasis. *J Am Acad Dermatol*. 1993 Apr;28(4):632-7. PMID: 8463467
22. Hayes, Inc. Comparative Effectiveness Review. Laser Therapy For Psoriasis. First published on April 25, 2019. Last reviewed and updated on April 7, 2022.
23. Health Technology Assessment Vol.4: No.40 [Griffiths C E M, Clark C M, Chalmers R J G, Li Wan Po A, Williams H C.] A systematic review of treatments for severe psoriasis. 2000.
24. Honigsmann, H. (2020). UVB therapy (narrow and broadband). UpToDate. Available at: <https://www.uptodate.com/contents/uvb-therapy-narrow-and-broadband>
25. Koek, MB, Buskens, E, Bruijnzeel-Koomen, CA, et al. (2006). Home ultraviolet B phototherapy for psoriasis: discrepancy between literature, guidelines, general opinions and actual use. Results of a literature review, a web search, and a questionnaire among dermatologists. *Br J Dermatol* 154.4: 701-11.
26. Koek, MB, Buskens, E, van Weelden, H, et al. (2009). Home versus outpatient ultraviolet B phototherapy for mild to severe psoriasis: pragmatic multicentre randomised controlled non-inferiority trial (PLUTO study). *BMJ* 338: b1542.
27. Mayo Clinic Staff. (2011) Definition of Psoriasis. Last Update: February 25, 2011. Mayo Clinic. Available: <http://www.mayoclinic.com/health/psoriasis/DS00193>. Date Accessed: May 20, 2011.
28. Medical Advisory Secretariat. (2009) Ultraviolet phototherapy management of moderate-to-severe plaque psoriasis: an evidence-based analysis. Ontario Health Technology Assessment Series. 9(27)
29. Menter, A, Korman, NJ, Elmets, CA, et al. (2010). Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. *J Am Acad Dermatol* 62.1: 114-35.

Phototherapies for the Treatment of Skin Conditions, continued

30. Mikhail M, Scheinfeld N. Psoriasis severity, scoring, and treatment with phototherapy and systemic medications. *Dermatology* Jan. 2005; Vol. 5, No. 1: 38-45.
31. Naldi L, Svensson A, Diepgen T, Elsner P, Grob JJ, Coenraads PJ, Bavinck JN, Williams H; European Dermato-Epidemiology Network. Randomized clinical trials for psoriasis 1977-2000: the EDEN survey. *J Invest Dermatol*. 2003 May;120(5):738-41. PMID: 12713574
32. Narbutt J, Holdrowicz A, & Lesiak A. Morphia – selected local treatment methods and their effectiveness. *Rheumatologia*. 2017; 55(6): 305–313. doi: 10.5114/reum.2017.72628
33. National Institute for Clinical Excellence (NICE). New treatments for moderate to severe psoriasis - appraisal (project).
34. National Psoriasis Foundation. (2011) Treating Psoriasis: Phototherapy. Last Update: 2011. National Psoriasis Foundation, Available: <http://www.psoriasis.org/netcommunity/Page.aspx?pid=430>. Date Accessed: May 20, 2011.
35. Nolan, BV, Yentzer, BA, Feldman, SR. (2010). A review of home phototherapy for psoriasis. *Dermatol Online J* 16.2: 1.
36. Pasker-de Jong PC, Wielink G, van der Valk PG, van der Wilt GJ. Treatment with UV-B for psoriasis and nonmelanoma skin cancer: a systematic review of the literature. *Arch Dermatol*. 1999 Jul;135(7):834-40. PMID: 10411159
37. Pearce DJ, Thomas CG, Fleischer AB Jr, Feldman SR. The cost of psoriasis therapies: considerations for therapy selection. *Dermatol Nurs*. 2004 Oct;16(5):421-8, 432. Review. PMID: 15624706
38. Rakel, D. (2007). *Integrative Medicine*. 2 ed. Philadelphia: Saunders Elsevier.
39. Rodewald EJ, Housman TS, Mellen BG, Feldman SR. The efficacy of 308nm laser treatment of psoriasis compared to historical controls. *Dermatol Online J*. 2001 Dec;7(2):4. PMID: 12165220
40. Spuls PI, Witkamp L, Bossuyt PM, Bos JD. A systematic review of five systemic treatments for severe psoriasis. *Br J Dermatol*. 1997 Dec;137(6):943-9. PMID: 9470912
41. Stern RS, Lunder EJ. Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-analysis. *Arch Dermatol*. 1998 Dec;134(12):1582-5. PMID: 9875197
42. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. *J Invest Dermatol Symp Proc*. 2004 Mar;9(2):136-9. PMID: 15083780
43. Stern, RS, Laird, N. (1994). The carcinogenic risk of treatments for severe psoriasis. *Photochemotherapy Follow-up Study*. *Cancer* 73.11: 2759-64.
44. Taneja A, Trehan M, Taylor CR. 308-nm excimer laser for the treatment of psoriasis: induration-based dosimetry. *Arch Dermatol*. 2003 Jun;139(6):759-64. PMID: 12810507
45. Tanghetti E, Gillis PR. Photometric and clinical assessment of localized UVB phototherapy systems for the high-dosage treatment of stable plaque psoriasis. *J Cosmet Laser Ther*. 2003 Jun;5(2):101-6. PMID: 12850797
46. The National Psoriasis Foundation, <https://www.psoriasis.org>.
47. Trehan M, Taylor CR. High-dose 308-nm excimer laser for the treatment of psoriasis. *J Am Acad Dermatol*. 2002 May;46(5):732-7. PMID: 12004316
48. Trehan M, Taylor CR. Medium-dose 308-nm excimer laser for the treatment of psoriasis. *J Am Acad Dermatol*. 2002 Nov;47(5):701-8. PMID: 12399761
49. Yentzer, BA, Yelverton, CB, Pearce, DJ, et al. (2008). Adherence to acitretin and home narrowband ultraviolet B phototherapy in patients with psoriasis. *J Am Acad Dermatol* 59.4: 577-81.
50. Yentzer, BA, Yelverton, CB, Simpson, GL, et al. (2009). Paradoxical effects of cost reduction measures in managed care systems for treatment of severe psoriasis. *Dermatol Online J* 15.4: 1.
51. Zanolli M. Phototherapy treatment of psoriasis today. *J Am Acad Dermatol* 2003; 49(2): S78-86.

Revision History

Revision Date	Summary of Changes
2/17/23	For Commercial Plan Policy, clarified timeframe requirement for aggressive standard therapy in criteria section #2: "SelectHealth covers office-based PUVA, narrowband UVB, and broadband UVB phototherapies for the treatment of atopic dermatitis, lichen planus, chronic idiopathic urticaria, morphea, and other related skin conditions, when the member has failed at least 3 months of aggressive standard therapy in the last 2 years. " Also, added phototherapy treatment for vitiligo as an exclusion: "SelectHealth does not cover any form of phototherapy for vitiligo; this is considered cosmetic."
4/16/24	For Commercial Plan Policy, clarified requirements for attempts at aggressive standard therapy: " Select Health covers office-based PUVA, narrowband UVB, and broadband UVB phototherapies for the treatment of atopic dermatitis, lichen planus, chronic idiopathic urticaria, morphea, and other related skin conditions, when the member has failed at least 3

Phototherapies for the Treatment of Skin Conditions, continued

	months of aggressive standard therapy in the last 2 years, <i>for any of the following therapies: topical therapy, oral immunosuppressants, or topical and/or oral steroids.</i>
12/12/24	For Commercial Plan Policy, modified requirements for home phototherapy in criterion #C-4a/b: "4. a) Provider has documented member as having demonstrated measurable improvement with initial treatment in the provider's office after a minimum of 16 visits occurring within a 60-day period; or b) If in-office therapy is not available, then rent-to-purchase UVB therapy will be available if the member has demonstrated measurable improvement after a minimum of 16 therapies within the 60-day period at home.
5/8/25	For Commercial Plan Policy, added treatment of polymorphous light eruption with PUVA phototherapy as a qualifying condition for coverage when criteria are met.

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate healthcare providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Select Health® makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. Select Health updates its Coverage Policies regularly, and reserves the right to amend these policies without notice to healthcare providers or Select Health members.

Members may contact Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Coverage Policy may call Select Health Provider Relations at (801) 442-3692.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Select Health.

"Intermountain Healthcare" and its accompanying logo, the marks of "Select Health" and its accompanying marks are protected and registered trademarks of the provider of this Service and or Intermountain Health Care, Inc., IHC Health Services, Inc., and Select Health, Inc. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association



MEDICAL POLICY

RADIATION THERAPY FOR BASAL AND SQUAMOUS CELL CARCINOMA

Policy # 661

Implementation Date: 8/1/23

Review Dates: 8/12/24

Revision Dates: 3/20/25, 7/14/25

Disclaimer:

1. Policies are subject to change without notice.
2. Policies outline coverage determinations for Select Health Commercial, Select Health Medicare (CMS), and Select Health Community Care (Medicaid) plans. Refer to the "Policy" section for more information.

Description

Non-melanomatous skin cancers (NMSC) encompass basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). NMSCs are the most prevalent malignancies in the Caucasian population. The incidence is rising in large part due to an aging population. Related mortality is low but considerable morbidity can result. The most common anatomical sites are those with the most sun exposure: the head, neck, shoulders, and back. The majority of NMSCs are BCC, with 25% being SCC. The healthcare burden of NMSC is considerable. Radiotherapy is typically offered to patients who are not candidates for Mohs surgery or who refuse surgical treatment. Anatomical location-specific considerations include facial sites that require complex procedures. Radiotherapy is being considered with more regularity as newer technologies have facilitated novel treatment techniques.

Several different types of radiotherapy can be used to treat BCC. External beam radiation therapy uses a linear accelerator to generate photons in the megavolt energy range. High-dose rate brachytherapy involves placement of a radioactive isotope into the patient within a body cavity, directly into tissue, or near the skin surface. More recently, electronic brachytherapy (EBT) and superficial radiation therapy (SRT) devices have become more commercially available. Electronic brachytherapy and SRT differ from traditional brachytherapy and radiation therapy in that neither are true brachytherapy techniques. While both EBT and SRT transmit radiation by placing a probe near or onto the skin, the dose is not delivered from a radioactive isotope; thus, these are technically forms of external beam radiation not brachytherapy. Additionally, the energy used in EBT and SRT is in the kilovolt range and therefore has been deemed low energy, unlike the high energy (in the megavolt range) emitted by external beam radiation therapy.

COMMERCIAL PLAN POLICY AND CHIP (CHILDREN'S HEALTH INSURANCE PROGRAM)

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request.

Select Health may cover superficial radiation therapy (SRT) for non-melanoma skin cancers, when the following criteria are met (must meet 1, or 2, or 3 and 4)

1. The presence of a low-risk cutaneous basal cell carcinoma (BCC) or high-risk BCC as per NCCN, ASTRO, and AAD guidelines with documentation that the patient is a nonsurgical candidate*, **OR**
2. The presence of a low-risk cutaneous squamous cell carcinoma (SCC) or high-risk SCC as per NCCN, ASTRO, and AAD guidelines with documentation that the patient is a nonsurgical candidate*, **OR**

Radiation Therapy for Basal and Squamous Cell Carcinoma, continued

3. The presence of a cutaneous SCC in situ as per NCCN, ASTRO and AAD guidelines with documentation that the patient is a nonsurgical candidate*.

AND

4. Accompanying documentation verifying the requirements outlined below is necessary:

All radiation oncology therapeutic services will be considered reasonable and necessary only when performed by an appropriately trained provider. The provider's training and expertise must have been acquired within the framework of an accredited residency and/or fellowship program in the applicable specialty/subspecialty, (i.e., radiation oncology **OR** by a qualified) dermatology program of training with didactic and clinical experience in radiation treatment

*Examples of nonsurgical candidates are patients where the surgery would cause loss of function, would result in significant morbidity, poor cosmesis in an anatomically sensitive area (e.g., ears, nose, lips, eyelids); or, when after documentation of shared decision making, the patient refuses surgery as a treatment option.

Select Health does not cover use of high-resolution ultrasound to guide SRT delivery and to assess lesion reduction during the superficial radiation treatment protocol as this is not supported by literature; this meets the plan's definition of experimental/investigational.

Select Health does not cover superficial radiation therapy for keloids as it is considered not medically necessary.

Select Health does not cover electronic brachytherapy for the treatment of non-melanoma skin cancers. There is insufficient long-term efficacy and safety data to support the use of electronic brachytherapy for these indications; this meets the plan's definition of experimental/investigational.

SELECT HEALTH MEDICARE (CMS)

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the Select Health Commercial policy applies. For the most up-to-date Medicare policies and coverage, please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp&> or [the manual website](#)

SELECT HEALTH COMMUNITY CARE (MEDICAID)

Select Health Community Care policies typically align with State of Utah Medicaid policy, including use of InterQual. There may be situations where NCD/LCD criteria or Select Health commercial policies are used. For the most up-to-date Medicaid policies and coverage, please visit their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Billing/Coding Information

Covered for the indications listed above when criteria are met

CPT CODES

77401 Radiation treatment delivery, superficial and/or ortho voltage, per day

Not covered: the following codes are considered experimental/investigational for the indications listed above

CPT CODES

0394T High dose rate electronic brachytherapy, skin surface application, per fraction, includes basic dosimetry, when performed

Radiation Therapy for Basal and Squamous Cell Carcinoma, continued

77387 Guidance for localization of target volume for delivery of radiation treatment, includes intrafraction tracking, when performed

Key References

1. ASTRO Guidelines. Definitive and Postoperative Radiation Therapy for Basal and Squamous Cell Cancers of the Skin. December 1, 2019.
2. CMS. Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC). Proposed LCD - Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC) (DL40176).
2. Hayes, Inc. Superficial Radiation Therapy for Treatment of Nonmelanoma Skin Cancer. Health Technology Brief. March 21, 2018.
3. NCCN Guidelines. Basal Cell Skin Cancer. Version 2.2025—February 7, 2025.
4. NCCN Guidelines. Squamous Cell Skin Cancer. Version 2.2025—February 7, 2025.

Revision History

Revision Date	Summary of Changes
3/20/25	For Commercial Plan Policy, added treatment of keloids as an exclusion for superficial radiation therapy.
7/14/25	For Commercial Plan Policy, revised to include coverage criteria for these procedures; and added the following exclusions: "Select Health does not cover use of high-resolution ultrasound to guide SRT delivery and to assess lesion reduction during the superficial radiation treatment protocols as this is not supported by literature; this meets the plan's definition of experimental/investigational. Select Health does not cover superficial radiation therapy for keloids as it is considered not medically necessary."

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate healthcare providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Select Health® makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. Select Health updates its Coverage Policies regularly, and reserves the right to amend these policies without notice to healthcare providers or Select Health members.

Members may contact Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Coverage Policy may call Select Health Provider Relations at (801) 442-3692.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Select Health.

"Intermountain Healthcare" and its accompanying logo, the marks of "Select Health" and its accompanying marks are protected and registered trademarks of the provider of this Service and or Intermountain Health Care, Inc., IHC Health Services, Inc., and Select Health, Inc. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association